

***Virginia Biosciences Health
Research Corporation***
dba: Virginia Catalyst

Achieving Competitive Critical Mass Through Collaboration

**Annual Report for Fiscal Year 2021
Submitted October 1, 2021 to:**

**Secretary of Commerce and Trade, the Chairs of the House
Appropriations and Senate Finance and Appropriations Committees,
the Director of the Department of Planning and Budget, and
Virginia Innovation Partnership Authority**

 **11** Grant Rounds Conducted

 **46** Funded Projects that Improve Human Health

AWARDED VS. ECONOMIC IMPACT

Through Round 11

● Awarded ● Matching Funds ● Follow-on Funding



 **200** High Paying Jobs Created

COLLABORATIVE STRENGTH

46 Projects involving 35 Industry Partners
 in collaboration with Virginia Universities



VBHRC Virginia Catalyst is a not-for-profit 501(c)(3) corporation created by the Virginia General Assembly and funded by the Commonwealth's General Fund and seven Virginia public research universities: EVMS, GMU, ODU, UVA, VCU, VT and W&M. Our mission is to stimulate and cultivate collaborations and partnerships among Virginia's research universities, major health systems, and industry to produce positive economic impact within the Commonwealth. Michael Grisham, CEO

*One-time COVID-19 Funding Round not included in totals

Forward

The 2020 Virginia Acts of Assembly, Chapter 1289 (approved May 21, 2020), Item 135 provides funding for the Virginia Biosciences Health Research Corporation (VBHRC), a 501(c)(3) non-stock corporation, to serve as a research consortium and catalyst to accelerate and focus life science research momentum at Virginia's universities (K.1).

This item also includes the requirement that you are provided, by October 1 of each year, a written report summarizing the activities of the VBHRC consortium. The report is to include a summary of how any funds disbursed to the consortium during the previous fiscal year were spent, and the consortium's progress during the fiscal year in expanding upon existing research opportunities and stimulating new research opportunities in the Commonwealth (K.6).

We are pleased to submit to you the following report to detail progress made on core objectives, with a focus on the results achieved during Fiscal Year 2021. Please note, as with our prior annual reports, we are continuing our practice of including details of ongoing efforts into the current fiscal year.

Statement from Mike Grisham, CEO

"On behalf of VBHRC Virginia Catalyst and its Board of Directors, we thank you for your continued support of these important and innovative efforts to advance commercialization of Virginia's life science innovations and create high-paying jobs in Virginia. This is achieved through collaborations with our research universities, health systems, and industry.

As always, if you have any questions or requests, or if we can be of any assistance, please do not hesitate to contact us!"

Mike Grisham
President and CEO
mgrisham@VirginiaCatalyst.org
804-543-5200

Suzanne Zeta, PhD, MBA
Vice President of Operations
suzeta@VirginiaCatalyst.org
804-937-3919

Virginia Biosciences Health Research Corporation Annual Report for Fiscal Year 2021

Executive Summary	i
Forward	ii
Table of Contents	iii
Overview of VBHRC	1
Progress on Core Objectives	
Grant Funding Program	3
Overview and Objectives	3
Project Management and Oversight Panel	3
Fiscal Year 2021 Awarded Projects	4
Economic Returns	4
COVID-19 Grant Round	5
Appendices	
Appendix A: Governance Overview	7
A.1 Members of Board of Directors	7
A.2 Members of Project Management and Oversight Panel	8
A.3 Members of Management	9
Appendix B: Funding History of VBHRC	11
Appendix C: Financial Statements and Independent Auditor's Report	
C.1 Fiscal Year 2021 Financial Statements	12
C.2 Fiscal Year 2021 Independent Auditor's Report	22
C.3 Fiscal Year 2022 Pro Forma Budget	39
Appendix D: Grant Funding Rounds	
D.1 Summary of Awarded Projects to Date	42
D.2 Summary of Economic Returns to Date	52
D.3 Summary of COVID-19 Grant Round	55
D.3.a Members of Subject Matter Expert Consultant Panel	55
D.3.b Summary of Awarded Projects	55
D.3.c Summary of Economic Returns to Date	56
Appendix E: Press Releases	
E.1 Grant Round 11: Awarded Projects	57
E.2 COVID-19 Grant Round: Call for Proposals	60
E.3 Grant Round 12: Call for Proposals	62

Overview of Virginia Biosciences Health Research Corporation

Established in 2013 as Virginia's research consortium the Virginia Biosciences Health Research Corporation (VBHRC) was founded through the vision and joint efforts of the Commonwealth of Virginia and the five (5) founding members consisting of Virginia's premiere research institutions: Virginia Commonwealth University, Eastern Virginia Medical School, George Mason University, Virginia Tech, and the University of Virginia. In 2014, Old Dominion University became the sixth member institution. In October 2016, William & Mary joined as the seventh member institution of this consortium but withdrew membership in 2021.

As stated in the 2020 Virginia Acts of Assembly (approved May 21, 2020), Chapter 1289, Item 135, the overarching purpose and focus of VBHRC is to stimulate and cultivate collaborations and partnerships among Virginia's research universities, major health systems, and industry to produce a positive economic impact within the Commonwealth. This is measured by tracking job creation and follow-on funding for commercializing Virginia's innovations. VBHRC's strategic initiatives increase corporate-sponsored, federal, industry, and philanthropic research funds brought into Virginia, resulting in commercialization of new technologies, formation of new companies, creation of jobs, and expansion of bioscience companies in Virginia.

VBHRC is governed by a Board of Directors (BOD)¹ with primary duties that include:

- Reviewing and approving the annual budget
- Reviewing annual and periodic financial statements and information
- Reviewing Chief Executive Officer's performance annually, establishing salary
- Reviewing and approving all program grant projects
- Reviewing and approving all supplier contracts over \$25,000
- Reviewing and approving all non-budgeted expenditures over \$10,000
- Reviewing and advising staff on internal controls and accounting policies and procedures
- Annually contracting for an audit of the VBHRC and meeting at least annually with the external auditor to review the results of the audit.

The BOD is comprised of a maximum of sixteen directors, nine of whom are ex-officio directors as follows:

- Secretary of Commerce and Trade of Virginia
- President and Chief Executive Officer, Virginia Economic Development Partnership Authority
- President of each of the (seven) applicable institutions

Each of the nine ex-officio directors may designate an employee of his or her agency or institution to act in his or her stead. The remaining seven directors represent the United States Department of Veterans Affairs, health care system providers in Virginia, life sciences companies, venture capital firms, and the biosciences industry in Virginia.

¹ [Appendix A](#) lists members of VBHRC Board of Directors, Project Management and Oversight Panel, and Management

The 2020 Virginia Acts of Assembly, Chapter 1289 (approved May 21, 2020), Item 135, K.1. provides funding for VBHRC for fiscal years 2021 and 2022 to achieve established core objectives. In addition, the President of each member university agreed to commit a cash contribution of \$50,000 each year.² As stated in the aforementioned Acts of Assembly, along with supporting the administrative, promotional and legal costs of establishing and administering the consortium, funding may be used to develop or maintain investments in research infrastructure tools to facilitate bioscience research (Item 135:K.2), and to capture and perform research in the biosciences (Item 135:K.3).

In fiscal year 2020, VBHRC was funded \$3,750,000 by the Commonwealth of Virginia and \$350,000 through the member institutions (\$50,000 per each year of the seven (7) member institutions), bringing the total funding for fiscal year 2019 to \$4,100,000.

In fiscal year 2021, VBHRC was funded \$3,750,000 by the Commonwealth of Virginia and \$350,000 through the member institutions (\$50,000 per each year of the seven (7) member institutions), bringing the total funding for fiscal year 2020 to \$4,100,000.

See [Appendix C](#) for Fiscal Year 2021 Financial Statements, Independent Auditor's Report, and Fiscal Year 2022 Budget.

Core Objectives

The aforementioned Acts of Assembly also include core objectives of VBHRC, a research consortium, to contract with private entities, foundations and other governmental sources to:

- capture and perform research in the biosciences,
- promote the development of bioscience infrastructure tools which can be used to facilitate additional research activities, and
- develop or maintain investments in research infrastructure tools to facilitate bioscience research.

The overarching purpose of these core objectives and efforts is to have a positive economic impact to the Commonwealth by increasing corporate-sponsored research resulting in commercialization of new technologies, formation of new companies, creation of jobs, and expansion of bioscience companies in Virginia.

VBHRC, doing business as *Virginia Catalyst*



As VBHRC expanded its work and initiatives of collaborations broadly across Virginia as well as funding from corporate-sponsored, federal and industry outside of Virginia, the need and benefits of an effective branding and marketing became apparent. In June 2017 the Commonwealth of Virginia, State Corporation Commission recognized VBHRC doing-business-as the *Virginia Catalyst*.

² [Appendix B](#) provides details regarding the funding history of VBHRC

Progress on Core Objectives

Grant Funding Program

Overview and Objectives

The Virginia Catalyst conducts formalized, competitive Grant Funding Rounds to:

- encourage collaborative partnerships between two or more Virginia research universities and an industry partner,
- fund the development and commercialization of life science projects that address major unmet needs for improving human health,
- accelerate commercialization of Virginia research university inventions and discoveries,
- increase Virginia's national and global competitiveness in the life sciences by creating critical mass through collaborations between and among Virginia's research universities, health systems, and industry partners,
- create jobs and economic growth in Virginia.

The eligibility requirements for obtaining funding through the Virginia Catalyst Grant Rounds are:

- Substantive collaboration between investigators from at least two (2) Virginia research universities³ and an industry partner,
- matching funds of at least 1:1 for the project. The match must be a cash dollar-for-dollar match, not in-kind services, nor a waiver of indirect overhead charges. Matching funds are verified by the Virginia Catalyst.

Awards range from \$200,000 to \$800,000 per project and are non-dilutive. All Virginia Catalyst funding is disbursed over the project period based upon verified completion of objective and measurable milestones. The Virginia Catalyst disburses the funds directly to the Prime University, not the industry partner. The Prime University then disburses funds to the Partner University and the Industry Partner.

Project Management and Oversight Panel

The Project Management and Oversight Panel⁴, the CEO, and the Board of Directors developed and approved criteria and standardized processes which govern the Virginia Catalyst Grant Rounds including:

- Project solicitation from institutions and companies
- Determination that eligibility requirements have been satisfied
- Project review for scientific rigor and impact on unmet needs for improving health

³ Virginia research universities and member institutions of the Virginia Catalyst (fiscal year 2021): University of Virginia, Virginia Commonwealth University, Eastern Virginia Medical School, George Mason University, Old Dominion University, Virginia Tech, William & Mary

⁴ [Appendix A](#) lists members of VBHRC Board of Directors, Project Management and Oversight Panel, and Management

- Project review for abilities of commercialization, obtaining follow-on funding, and job creation
- Progress reporting by the project team including progress towards milestones and continuation of the project
- Related project management issues and decisions.

Fiscal Year 2021 Awarded Projects⁵

Virginia Catalyst conducted Grant Round 11, a one-time COVID-19 Grant Round, and opened Grant Round 12 in fiscal year 2021. See [Appendix D.1](#) for a summary of all awarded projects to date.

Grant Round 11

In October 2020, VBHRC funded three (3) projects for a total amount \$2.1 million. These projects brought a total of \$4.9 million in matching funds and involved:

- Five (5) Virginia research universities, and
- Three (3) industry partners

As of June 30, 2021, each of these projects were open and progressing towards milestones as per their respective award agreements. One of these projects has already secured \$1.1 million in follow-on funding and created 7 new jobs in Virginia.

Economic Returns⁶

The Virginia Catalyst awarded its first Grant Rounds in December 2013, and as of June 30, 2021, has conducted eleven cycles of Grant Rounds, along with a one-time COVID-19 Grant Round. See [Appendix D.2](#) for details on economic returns to date.

Cumulatively through June 30, 2021

***The Virginia Catalyst funded a total of
\$21.3 million to 46 collaborative projects.***

***Together these projects brought a total of:
\$39.3 million in matching funds, and involved
Six (6) Virginia research universities, and thirty-five (35) industry partners
And resulted in: \$245 million in follow-on funding, and
206 new high-paying jobs created in Virginia***

⁵ [Appendix D.1](#) provides a summary of all awarded projects to date

⁶ [Appendix D.2](#) provides details on economic returns to date

COVID-19 Grant Round

During fiscal year 2021 the Virginia Catalyst conducted a one-time COVID-19 Grant Round in accordance with the 2020 Virginia State Budget, Special Session I, HB 5005, Item 135.K.1, which was amended to insert “and \$5,000,000 the first year from nongeneral funds,” and added K.9.a:

“The VBHRC shall administer a one-time grant program designed to support the acceleration of clinical testing of a therapeutic drug that treats clinical symptoms caused by COVID-19. VBHRC shall consult with subject matter experts in the healthcare industry or academia to develop criteria for awarding funds provided in paragraph P.3. of this item. At a minimum, these criteria must include: (i) the company was founded in and is headquartered in Virginia; and (ii) the company is actively conducting a Phase 1 or Phase 2 clinical trial of a therapeutic drug approved by the United States Food and Drug Administration (“FDA”) to treat life-threatening symptoms caused by COVID-19. In awarding these funds, the board of directors of the VBHRC may waive the requirements that (i) two of the participating institutions are actively and significantly involved in collaborating on the research, and (ii) funding be matched at least dollar-for-dollar by funding provided by private entities, foundations and other governmental sources.”

Subject Matter Experts

Unique to the COVID-19 Grant Round, the Virginia Catalyst Board of Directors selected a team of scientific experts associated with Virginia research universities and medical centers to write a report on the scientific merit and relevance of the proposed therapeutic. This Subject Matter Expert (SME) Consultant Panel⁷ reviewed applications to the COVID-19 Grant Round and conducted conference calls with the scientific members of each applicant team. Their report on each of the applications was provided to the Project Management and Oversight Panel for consideration along with the proposal presentation.

Awarded Projects⁸

In March 2021, VBHRC funded three (3) projects for a total of amount \$4,985,000. These projects brought a total of \$6 million in matching funds and involved:

- Two (2) Virginia research universities, and
- Three (3) industry partners

As of June 30, 2021, all of these projects were open and progressing towards milestones as per their respective award agreements. One of these projects has already secured \$1.3 million in follow-on funding and created 7 new jobs in Virginia.⁹

⁷ [Appendix D.3.a](#) lists members of the SME Consultant Panel

⁸ [Appendix D.3.b](#) Provides details on awarded projects in COVID-19 Grant Round

⁹ [Appendix D.3.c](#) provides details on economic returns to date

[this page intentionally left blank]

Appendix A: Governance Overview

Non-government related positions on the Board of Directors, as well as the Project Management and Oversight Panel, are filled on a pro bono basis by qualified individuals who hold important bioscience-related expertise, value the public service nature of this position, and possess a sincere interest in helping to advance Virginia's bioscience community. VBHRC Virginia Catalyst and Virginia Innovation Partnership Authority are deeply grateful for their voluntary contributions to the Commonwealth.

A.1 Members of Board of Directors

As per the Articles of Incorporation of VBHRC, as amended July 16, 2019, VBHRC shall be managed by a board of directors consisting of a maximum of sixteen directors, nine of whom shall be ex-officio directors designated by entities controlled by the Commonwealth of Virginia. This is intended to satisfy Article IV, §16 of the Constitution of Virginia.

The nine ex-officio directors shall be: the Secretary of Commerce and Trade of Virginia; the President and Chief Executive Officer of the Virginia Economic Development Partnership Authority; the president of the University of Virginia; the president of the Virginia Polytechnic Institute and State University; the president of George Mason University; the president of Virginia Commonwealth University; the president of Eastern Virginia Medical School; the president of Old Dominion University; and the president of the College of William & Mary. Each of the nine ex-officio directors may, in a writing signed by the ex-officio director, designate an employee of his or her agency or institution to act in his or her stead or terminate or replace an earlier designation. The Chair and Vice-Chair of the Board of Directors need not be ex-officio directors, but any ex-officio director may, by written notice to the Chair, require a meeting of the Board of Directors, and may require any matter or motion to be placed upon the agenda and voted upon.

With respect to the remaining seven directors, one (1) shall be a representative of the United States Department of Veterans Affairs, two (2) shall be representatives of statewide health care system providers in Virginia, and the board of directors shall designate an additional three directors representing life sciences company, venture capital firm that regularly invests in life science companies, and statewide representative of the biosciences industry in Virginia.

The current members of the VBHRC Virginia Catalyst Board of Directors are as follows:

Designated Board Seat	Current Board Member
1. Secretary of Commerce and Trade of Virginia or his/her designee	Cassidy Rasnick Deputy Secretary of Commerce and Trade Commonwealth of Virginia

2. President and Chief Executive Officer of the Virginia Economic Development Partnership Authority or designee	Vince Barnett Vice President, Business Investment
3. President of the University of Virginia or his/her designee	Melur K. Ramasubramanian, Ph.D. Interim Vice President for Research
4. President of the Virginia Polytechnic Institute and State University or his/her designee	Michael Friedlander, Ph.D. Founding Exe.Dir, Virginia Tech Carilion Research Institute, Associate Provost
5. President of George Mason University or his/her designee	Andre Marshall, Ph.D. Vice President for Research, Innovation, and Economic Impact
6. President of Virginia Commonwealth University or his/her designee	Srirama Rao, Ph.D. Vice President for Research and Innovation
7. President of Eastern Virginia Medical School or his/her designee	William J. Wasilenko, Ph.D. Vice Dean for Research
8. President of Old Dominion University or his/her designee	Morris Foster, Ph.D. Vice President for Research
9. President of College of William and Mary or his/her designee	Dennis Manos, Ph.D. Vice Provost for Research and Graduate/Professional Studies
10. Representative of the United States Department of Veteran Affairs	David X. Cifu, M.D. National Director for PM&R Services
11. Representative of statewide health care system provider in Virginia	Howard P. Kern President and CEO, Sentara Healthcare
12. Representative of statewide health care system provider in Virginia	Mickey Kim, MD, MBA Senior Vice President, Corp Dev. and Strategy CareDx
13. Representative of a life sciences company	Jeff Conroy Founder and CEO, Embody LLC
14. Representative of a venture capital firm that regularly invests in life sciences companies	Thomas D. Roberts, III General Partner Harbert Management Corporation
15. Representative of a venture capital firm that regularly invests in life sciences companies	Kyp Sirinakis Co-Founder and Managing Director Epidarex Capital
16. Statewide representative of the biosciences industry in Virginia	Jeffrey M. Gallagher Former CEO, Virginia Bio

A.2 Members of Project Management and Oversight Panel

As per the Articles of Incorporation of VBHRC, as amended March 7, 2017, the Board of Directors shall establish a Project Management and Oversight Panel with maximum of eleven members, which include up to six (6) scientists, one of which will be a medical doctor or clinical

practitioner; three (3) shall be representative of life science companies; and two (2) shall be representative of venture capital firms that actively invest in life science companies. The current members of the VBHRC Virginia Catalyst Project Management and Oversight Committee are as follows:

Designated Panel Seat	Current Panel Member
1. Science and Clinical	Ali Andalibi, Ph.D. Associate Dean of Research George Mason University
2. Science and Clinical	O. John Semmes, Ph.D. Director, Leroy Canoles Jr. Cancer Research Center Eastern Virginia Medical School
3. Science and Clinical	George S. Bloom, Ph.D. Professor of Biology, Cell Biology and Neuroscience Director, Neuroscience Undergraduate Program, University of Virginia
4. Science and Clinical	Charles Anamelechi, Ph.D. Healthcare Strategy Manager, Monitor Deloitte
5. Science and Clinical	(Recruiting for Open Seat)
6. Life Science Company	Jeff Pompeo President and CEO, CareTaker Medical, LLC
7. Life Science Company	Rony Thomas President and CEO, LifeNet Health, Inc.
8. Life Science Company	Gerard Eldering President, Innovate Tech Ventures
9. Life Science Company	James C. Powers Chairman and CEO, Hemoshear, LLC
10. Venture Capital Firm	Bob Creeden Managing Director UVA Seed Fund and New Ventures
11. Venture Capital Firm	Scott Meza Shareholder and Attorney at Law, Greenberg Traurig
12. Venture Capital Firm	Monique Adams Executive Director, 757 Angels Group

A.3 Members of Management

As per the Articles of Incorporation of VBHRC, as amended March 7, 2017, the officers of VBHRC shall consist of a President, and such other officers and assistant officers and agents as may be deemed necessary by the Board of Directors. The President shall be the chief executive officer, shall have active executive management of the operations of VBHRC subject to the control of the Board of Directors.

Mike Grisham, MBA
President and CEO

Mike Grisham has served as President and CEO of VBHRC Virginia Catalyst since 2014. Prior to this he is the Founder and CEO of GPB Scientific, Inc. He has extensive experience in biosciences, building diagnostic and healthcare companies. Mr. Grisham founded and served as CEO of Celective DX (acquired by On-Q-ity); Verinata Health Inc. (acquired by Illumina); and Paradigm Health Corporation (acquired by Alere). Grisham holds a BA from University of California, Berkeley and an MBA from Stanford Graduate School of Business.

Suzanne Zeta, PhD, MBA
Vice President of Operations

In July 2018, Dr. Zeta joined VBHRC Virginia Catalyst as Vice President of Operations. Prior to this, Dr. Zeta worked for VBHRC to develop a marketing portfolio and provide support for the Virginia Neuroscience Initiative. Previously a member of Virginia Commonwealth University's Department of Physical Medicine and Rehabilitation, her clinical practice, instruction, research, and nationwide presentations led to recognition as a leader and expert in oncology rehabilitation. Taylor also has extensive healthcare management experience including serving as a Regional Director of Operations for American Retirement Corporation and Brookdale Senior Living. Along with being a licensed occupational therapist and having a Master of Business Administration in Healthcare Management degree, Zeta obtained a Doctor of Philosophy degree in Health Related Sciences from Virginia Commonwealth University.

[remainder of this page intentionally left blank]

Appendix B: Funding History of VBHRC

The founding members of VBHRC were Virginia's premiere research institutions: Virginia Commonwealth University, Eastern Virginia Medical School, George Mason University, Virginia Polytechnic Institute and State University and the University of Virginia. Old Dominion University became the sixth member of the consortium effective in 2014, and effective in Fiscal Year 2017, the College of William & Mary became the seventh member of the consortium but withdrew in 2021.

The Commonwealth of Virginia committed funding for Fiscal Years 2013 and 2014 to establish the core objectives of the consortium. In addition to this funding, the President of each member university agreed to commit a cash contribution to participate. The Commonwealth's commitment during those two fiscal years totaled \$5 million, supplemented by a \$100,000 contribution from each member university, distributed as \$50,000 each year.

Funds from Fiscal Years 2013 and 2014 carried over to Fiscal Year 2015. Therefore there was not additional funding from the Commonwealth in Fiscal Year 2015.

For Fiscal Year 2016, VBHRC received \$2,500,000 in funding from the Commonwealth and a total of \$300,000 (\$50,000 each) from its member universities.

In Fiscal Year 2017, VBHRC was funded \$2,500,000 by the Commonwealth of Virginia and \$350,000 through the member institutions (\$50,000 per each year of the seven (7) member institutions), bringing the total funding for Fiscal Year 2017 to \$2,850,000.

In Fiscal Year 2018, VBHRC was funded \$3,750,000 by the Commonwealth of Virginia and \$350,000 through the member institutions (\$50,000 per each year of the seven (7) member institutions), bringing the total funding for Fiscal Year 2018 to \$4,100,000.

In Fiscal Year 2019, VBHRC was funded \$3,750,000 by the Commonwealth of Virginia and \$350,000 through the member institutions (\$50,000 per each year of the seven (7) member institutions), bringing the total funding for Fiscal Year 2019 to \$4,100,000.

In Fiscal Year 2020, VBHRC was funded \$3,750,000 by the Commonwealth of Virginia and \$350,000 through the member institutions (\$50,000 per each year of the seven (7) member institutions), bringing the total funding for Fiscal Year 2019 to \$4,100,000.

[remainder of this page intentionally left blank]

Appendix C: Financial Statements and Independent Auditor's Report

C.1 Fiscal Year 2021: Financial Statements



Financial Statements For the Twelve Months Ended June 30, 2021 Table of Contents

	<u>Page</u>
Statement of Financial Position	1
Statement of Activities – Current Month, Prior Month and Year to Date	2-3
Statement of Activities – Budget vs Actual	4-5
Project Funding Status by Round	6-7
Funding Allocations by Prime University	8
Grant Funding Allocations to Date by University	9

BASIS OF ACCOUNTING. These statements are prepared in accordance with generally accepted accounting principles (GAAP); however, all disclosures required by GAAP have been omitted.

NO ASSURANCE. These financial statements have not been audited or reviewed and no CPA provides any assurance on them

Virginia Biosciences Health Research Corporation
Statement of Financial Position
As of June 30, 2021

	Jun 30, 21
ASSETS	
Current Assets	
Checking/Savings	
100000 · BB&T Checking 3407	8,840,886.51
105000 · BB&T MM 5225	1,319,798.74
Total Checking/Savings	9,960,465.25
Accounts Receivable	
120000 · Commonwealth of VA FY 2020 Rec	3,750,000.00
120500 · University Pledges Receivable	300,000.00
Total Accounts Receivable	4,050,000.00
Total Current Assets	14,010,465.25
TOTAL ASSETS	14,010,465.25
LIABILITIES & EQUITY	
Liabilities	
Current Liabilities	
Accounts Payable	
200000 · Accounts Payable	152,728.50
Total Accounts Payable	152,728.50
Total Current Liabilities	152,728.50
Total Liabilities	152,728.50
Equity	
310000 · Net Assets w/o Donor Restrict	
311000 · Uncommitted and Relinquished	-2,325,798.22
312000 · Committed to Projects	2,198,799.82
Total 310000 · Net Assets w/o Donor Restrict	-126,998.40
320000 · Net Assets with Donor Restrict	
321000 · Time Restricted	7,500,000.00
Total 320000 · Net Assets with Donor Restrict	7,500,000.00
380000 · Retained Earnings	4,211,822.70
Net Income	2,272,912.45
Total Equity	13,857,736.75
TOTAL LIABILITIES & EQUITY	14,010,465.25

No CPA provides any assurance on these financial statements

Page 1

Virginia Biosciences Health Research Corporation
Statement of Activities - Current Month, Prior Month & YTD
June 2021

	Jun 21	May 21	Jul '20 - Jun...
Ordinary Income/Expense			
Income			
400000 · Virginia General Assembly			
400500 · Program support	0.00	0.00	5,000,000.00
Total 400000 · Virginia General Assembly	0.00	0.00	5,000,000.00
410000 · Member University Contributions			
411000 · Eastern Va Medical School	50,000.00	0.00	50,000.00
412500 · George Mason University	50,000.00	0.00	50,000.00
413100 · Old Dominion University	50,000.00	0.00	50,000.00
413000 · University of Virginia	50,000.00	0.00	50,000.00
412000 · Virginia Commonwealth	50,000.00	0.00	50,000.00
410500 · Virginia Tech	50,000.00	0.00	50,000.00
Total 410000 · Member University Contributions	300,000.00	0.00	300,000.00
440000 · Other Income	10.85	11.21	131.81
Total Income	300,010.85	11.21	5,300,131.81
Gross Profit	300,010.85	11.21	5,300,131.81
Expense			
500000 · Program Expenses			
510000 · Collaborative Grant Program			
510600 · Round 6			
510606 · VoltMed INSPIRE	0.00	0.00	50,000.00
Total 510600 · Round 6	0.00	0.00	50,000.00
510800 · Round 8			
510806 · Wynn Vision	0.00	0.00	5,000.00
Total 510800 · Round 8	0.00	0.00	5,000.00
510900 · Round 9			
510902 · 902 BrightSpec VCU	0.00	0.00	180,000.00
510903 · 903 Ceres UVA	0.00	0.00	65,000.00
510904 · 904 Perthera - UVA / EVMS	15,000.00	0.00	35,000.00
Total 510900 · Round 9	15,000.00	0.00	260,000.00
511000 · Round 10			
511001 · 1001 CytoRecovery	0.00	0.00	182,000.00
511002 · 1002 InterLeukin	0.00	0.00	250,000.00
511003 · 1003 Lytos	0.00	0.00	257,000.00
511004 · 1004 Monet	0.00	0.00	200,000.00
511005 · 1005 Rivanna	150,000.00	200,000.00	600,000.00
511006 · 1006 Tympanogen	0.00	0.00	230,000.00
Total 511000 · Round 10	150,000.00	200,000.00	1,719,000.00
511100 · Round 11			
511101 · 1101 Contraline	0.00	0.00	107,800.00
511102 · 1102 ISOThrive	0.00	0.00	45,000.00
511103 · 1103 Meru	209,100.00	0.00	417,400.00
Total 511100 · Round 11	209,100.00	0.00	570,200.00
Total 510000 · Collaborative Grant Program	374,100.00	200,000.00	2,804,200.00
590000 · Support and development			
590100 · Salaries and Benefits			
590110 · Salaries and Wages	24,297.08	24,297.08	272,370.95
590120 · Payroll Taxes	1,858.72	1,858.72	17,193.47
590130 · Other Benefits	2,067.00	2,067.00	37,779.98
Total 590100 · Salaries and Benefits	28,222.80	28,222.80	327,344.40

No CPA provides any assurance on these financial statements

Page 2

Virginia Biosciences Health Research Corporation
Statement of Activities - Current Month, Prior Month & YTD
June 2021

	Jun 21	May 21	Jul '20 - Jun...
590200 · Program development			
590210 · Advertising - Press Releases	0.00	850.00	2,550.00
590250 · Memberships and sponsorships	0.00	0.00	18,750.00
590270 · Consulting fees	0.00	0.00	6,000.00
Total 590200 · Program development	0.00	850.00	27,300.00
Total 590000 · Support and development	28,222.80	29,072.80	354,644.40
Total 500000 · Program Expenses	402,322.80	229,072.80	2,958,844.40
600000 · General and administrative			
604000 · Accounting services	1,872.40	1,872.40	24,553.81
606000 · Audit and tax returns	0.00	0.00	11,275.00
612000 · Web Site	424.84	0.00	424.84
615000 · Dues and Subscriptions	544.89	0.00	544.89
617000 · Legal Expenses	2,369.00	0.00	27,261.75
619000 · Office Rent	258.13	258.13	2,831.30
621000 · Parking	85.00	85.00	935.00
624000 · Telephone	548.57	0.00	548.57
Total 600000 · General and administrative	6,102.83	2,215.53	68,374.96
Total Expense	408,425.43	231,288.33	3,027,219.36
Net Ordinary Income	-108,414.58	-231,277.12	2,272,912.45
Net Income	-108,414.58	-231,277.12	2,272,912.45

No CPA provides any assurance on these financial statements

Page 3

Virginia Biosciences Health Research Corporation
Statement of Activities Budget vs. Actual
 July 2020 through June 2021

	Jul '20 - Ju...	Budget	% of B...
Ordinary Income/Expense			
Income			
400000 · Virginia General Assembly			
400500 · Program support	5,000,000.00	3,250,000.00	153.8%
401000 · General & admin. support	0.00	500,000.00	0.0%
Total 400000 · Virginia General Assembly	5,000,000.00	3,750,000.00	133.3%
410000 · Member University Contributions			
413200 · William & Mary	0.00	50,000.00	0.0%
411000 · Eastern Va Medical School	50,000.00	50,000.00	100.0%
412500 · George Mason University	50,000.00	50,000.00	100.0%
413100 · Old Dominion University	50,000.00	50,000.00	100.0%
413000 · University of Virginia	50,000.00	50,000.00	100.0%
412000 · Virginia Commonwealth	50,000.00	50,000.00	100.0%
410500 · Virginia Tech	50,000.00	50,000.00	100.0%
Total 410000 · Member University Contributions	300,000.00	350,000.00	85.7%
440000 · Other Income	131.81		
Total Income	5,300,131.81	4,100,000.00	129.3%
Gross Profit	5,300,131.81	4,100,000.00	129.3%
Expense			
500000 · Program Expenses			
510000 · Collaborative Grant Program			
510600 · Round 6			
510606 · VoltMed INSPIRE	50,000.00		
510600 · Round 6 - Other	0.00	155,000.00	0.0%
Total 510600 · Round 6	50,000.00	155,000.00	32.3%
510700 · Round 7	0.00	597,778.00	0.0%
510800 · Round 8			
510806 · Wynn Vision	5,000.00		
510800 · Round 8 - Other	0.00	65,000.00	0.0%
Total 510800 · Round 8	5,000.00	65,000.00	7.7%
510900 · Round 9			
510902 · 902 BrightSpec VCU	180,000.00		
510903 · 903 Ceres UVA	65,000.00		
510904 · 904 Perthera - UVA / EVMS	35,000.00		
510900 · Round 9 - Other	0.00	417,500.00	0.0%
Total 510900 · Round 9	280,000.00	417,500.00	62.3%
511000 · Round 10			
511001 · 1001 CytoRecovery	182,000.00		
511002 · 1002 InterLeukin	250,000.00		
511003 · 1003 Lytos	257,000.00		
511004 · 1004 Monet	200,000.00		
511005 · 1005 Rivanna	600,000.00		
511006 · 1006 Tympanogen	230,000.00		
511000 · Round 10 - Other	0.00	2,348,000.00	0.0%
Total 511000 · Round 10	1,719,000.00	2,348,000.00	73.2%
511100 · Round 11			
511101 · 1101 Contraline	107,800.00		
511102 · 1102 ISOThrive	45,000.00		
511103 · 1103 Meru	417,400.00		
511100 · Round 11 - Other	0.00	1,000,000.00	0.0%
Total 511100 · Round 11	570,200.00	1,000,000.00	57.0%

No CPA provides any assurance on these financial statements

Page 4

Virginia Biosciences Health Research Corporation
Statement of Activities Budget vs. Actual
 July 2020 through June 2021

	Jul '20 - Ju...	Budget	% of B...
511200 · Round 12	0.00	600,000.00	0.0%
Total 510000 · Collaborative Grant Program	2,804,200.00	5,183,278.00	50.2%
590000 · Support and development			
590100 · Salaries and Benefits			
590110 · Salaries and Wages	272,370.95	276,000.00	98.7%
590120 · Payroll Taxes	17,193.47	22,950.00	74.9%
590130 · Other Benefits	37,779.98	24,000.00	157.4%
Total 590100 · Salaries and Benefits	327,344.40	322,950.00	101.4%
590200 · Program development			
590210 · Advertising - Press Releases	2,550.00	2,500.00	102.0%
590230 · Conferences	0.00	4,000.00	0.0%
590240 · Meals and Entertainment	0.00	1,000.00	0.0%
590250 · Memberships and sponsorships	18,750.00	25,000.00	75.0%
590260 · Travel and lodging	0.00	4,000.00	0.0%
590270 · Consulting fees	6,000.00		
590280 · Other program development exp.	0.00	800.00	0.0%
Total 590200 · Program development	27,300.00	37,300.00	73.2%
Total 590000 · Support and development	354,644.40	360,250.00	98.4%
Total 500000 · Program Expenses	2,958,844.40	5,543,528.00	53.4%
600000 · General and administrative			
604000 · Accounting services	24,553.81	24,000.00	102.3%
606000 · Audit and tax returns	11,275.00	10,000.00	112.8%
608000 · Board of Directors Expense	0.00	1,000.00	0.0%
612000 · Web Site	424.84	400.00	106.2%
615000 · Dues and Subscriptions	544.69		
616000 · Insurance	0.00	500.00	0.0%
617000 · Legal Expenses	27,261.75	18,000.00	151.5%
618000 · Office and Computer Supplies	0.00	1,000.00	0.0%
619000 · Office Rent	2,831.30	4,000.00	70.8%
621000 · Parking	935.00	1,000.00	93.5%
622000 · Postage	0.00	200.00	0.0%
624000 · Telephone	548.57	1,250.00	43.9%
Total 600000 · General and administrative	68,374.96	61,350.00	111.5%
Total Expense	3,027,219.36	5,604,878.00	54.0%
Net Ordinary Income	2,272,912.45	-1,504,878.00	-151.0%
Net Income	2,272,912.45	-1,504,878.00	-151.0%

No CPA provides any assurance on these financial statements

Page 5

VIRGINIA BIOSCIENCES HEALTH RESEARCH CORPORATION
Project Awards, Allocations to Date, Funds Relinquished, and Remaining Awards
As of June 30, 2021

Round	Company	Lead School	Amount Awarded	Allocation Awarded	Funds Forfeited	Award Remaining
Round 01	BioTherapeutics		400,000	400,000	-	-
	Cavion LLC		200,000	200,000	-	-
	FirstString		200,000	200,000	-	-
	HemoShear		450,000	450,000	-	-
Round 01 Total			1,250,000	1,250,000	-	-
Round 02	Gencia		400,000	400,000	-	-
	LifeNet Health		255,000	255,000	-	-
	Neoantigenics		348,729	348,729	-	-
	SphynKx		400,000	400,000	-	-
Round 02 Total			1,403,729	1,403,729	-	-
Round 03	OncoSec Medical		585,000	585,000	-	-
	PhenoCHIP		270,000	270,000	-	-
	US Probe		536,000	406,000	130,000	-
Round 03 Total			1,391,000	1,261,000	130,000	-
Round 04	BioTherapeutics		400,000	400,000	-	-
	BrightSpec		400,000	400,000	-	-
	Ceres Nanotrap		500,000	500,000	-	-
	Embody		634,500	634,500	-	-
	FirstString		290,000	290,000	-	-
Round 04 Total			2,224,500	2,224,500	-	-
Round 05	Cavion LLC		306,985	306,985	-	-
	VoltMed		380,000	380,000	-	-
Round 05 Total			686,985	686,985	-	-
Round 06	BioTherapeutics		800,000	800,000	-	-
	Propagenix		425,000	320,000	105,000	-
	Pulse Biosciences		300,000	300,000	-	-
	Sanyal Biotechnology		100,000	100,000	-	-
	SerpinPharma		400,000	400,000	-	-
	VoltMed		800,000	800,000	-	-
Round 06 Total			2,825,000	2,720,000	105,000	-
Round 07	ImmunArray		500,000	180,000	320,000	-
	Indivior		500,000	222,222	277,778	-
	ReAlta Live Sciences		400,000	339,122	60,878	-
Round 07 Total			1,400,000	741,344	658,656	-

No CPA provides any assurance on these financial statements

Page 6

VIRGINIA BIOSCIENCES HEALTH RESEARCH CORPORATION
Project Awards, Allocations to Date, Funds Relinquished, and Remaining Awards
As of June 30, 2021

Round	Company	Lead School	Amount Awarded	Allocation Awarded	Funds Forfeited	Award Remaining
Round 08	BrightSpec		400,000	400,000	-	-
	Continuum Biosciences		400,000	400,000	-	-
	Embody		800,000	795,000	-	5,000
	LifeNet Health		250,000	245,000	-	5,000
	SerpinPharma		350,000	350,000	-	-
	WynnVision		510,000	510,000	-	-
Round 08 Total			2,710,000	2,700,000	-	10,000
Round 09	AgroSpheres		600,000	600,000	-	-
	BrightSpec		400,000	400,000	-	-
	Ceres Nanotrap		600,000	570,000	-	30,000
	Perthera		500,000	500,000	-	-
Round 09 Total			2,100,000	2,070,000	-	30,000
Round 10	CytoRecovery		400,000	382,000	-	18,000
	InterLeukin		700,000	440,000	-	260,000
	Lytos		500,000	394,000	-	106,000
	Monet		400,000	275,000	-	125,000
	Rivanna		800,000	750,000	-	50,000
	Tympanogen		500,000	430,000	-	70,000
Round 10 Total			3,300,000	2,671,000	-	629,000
Round 11	Contraline		600,000	107,800	-	492,200
	ISOThrive		800,000	45,000	-	755,000
	Meru		700,000	417,400	-	282,600
Round 11 Total			2,100,000	570,200	-	1,529,800
Grand Total			\$ 21,391,214	\$ 18,298,758	893,656	2,198,800

No CPA provides any assurance on these financial statements







Page 7

VIRGINIA BIOSCIENCES HEALTH RESEARCH CORPORATION
 Funding Allocations by Prime University
 As of June 30, 2021

	Funding Allocations by Prime University					
	EVMS	GMU	ODU	UVA	VA Tech	VCU
Round 01	\$ -	\$ -	\$ -	\$ 650,000	\$ 600,000	\$ -
Round 02	255,000	-	-	348,729	400,000	400,000
Round 03	-	-	585,000	-	270,000	536,000
Round 04	-	500,000	634,500	400,000	690,000	-
Round 05	-	-	-	306,985	380,000	-
Round 06	100,000	400,000	300,000	-	1,600,000	425,000
Round 07	400,000	-	-	-	500,000	500,000
Round 08	-	350,000	1,050,000	-	400,000	910,000
Round 09	-	-	-	1,100,000	600,000	400,000
Round 10	500,000	400,000	-	1,300,000	400,000	700,000
Round 11	800,000	-	-	600,000	-	700,000
Total	\$ 2,055,000	\$ 1,650,000	\$ 2,569,500	\$ 4,705,714	\$ 5,840,000	\$ 4,571,000

No CPA provides any assurance on these financial statements

Page 8

Grant Funding Disbursements to Universities through June 30, 2021							
Project	Total Award	 EVMS	 GMU	 ODU	 UVA	 VCU	 VT
101 BioTherapeutics-VT-VCU	\$400,000	\$0	\$0	\$0	\$0	\$19,500	\$42,900
102 Cavion-UVA-VCU	\$200,000	\$0	\$0	\$0	\$130,917	\$69,083	\$0
103 FirstString-VT-UVA	\$200,000	\$0	\$0	\$0	\$25,000	\$0	\$175,000
104 HemoShear-UVA-GMU	\$450,000	\$0	\$76,175	\$0	\$42,308	\$0	\$0
Round 1	\$1,250,000	\$0	\$76,175	\$0	\$198,225	\$88,583	\$217,900
201 Gencia-VCU-UVA	\$400,000	\$0	\$0	\$0	\$200,000	\$200,000	\$0
202 LifeNet-EVMS-UVA	\$255,000	\$111,516	\$0	\$0	\$143,484	\$0	\$0
203 Neoantigenics-UVA-VCU	\$348,729	\$0	\$0	\$0	\$229,428	\$119,301	\$0
204 Sphynkx-VT-UVA	\$400,000	\$0	\$0	\$0	\$119,900	\$0	\$112,100
Round 2	\$1,403,729	\$111,516	\$0	\$0	\$692,812	\$319,301	\$112,100
301 OncoSec-ODU-EVMS	\$585,000	\$234,000	\$0	\$351,000	\$0	\$0	\$0
302 PhenoChlp-VT-UVA	\$270,000	\$0	\$0	\$0	\$75,000	\$0	\$195,000
303 USProbe-VCU-ODU	\$536,000	\$0	\$0	\$60,000	\$0	\$175,000	\$0
Round 3	\$1,391,000	\$234,000	\$0	\$411,000	\$75,000	\$175,000	\$195,000
401 BioTherapeutics-VT-VCU	\$400,000	\$0	\$0	\$0	\$0	\$29,900	\$39,000
402 BrightSpec-UVA-VCU	\$400,000	\$0	\$0	\$0	\$250,000	\$150,000	\$0
403 Ceres-GMU-VT	\$500,000	\$0	\$145,190	\$0	\$0	\$0	\$64,669
404 Embody-ODU-EVMS	\$634,500	\$60,000	\$0	\$424,500	\$0	\$0	\$0
405 FirstString-VT-UVA	\$290,000	\$0	\$0	\$0	\$39,000	\$0	\$251,000
Round 4	\$2,224,500	\$60,000	\$145,190	\$424,500	\$289,000	\$179,900	\$354,669
501 Cavion-UVA-GMU	\$306,985	\$0	\$117,448	\$0	\$189,537	\$0	\$0
502 VoltMed-VT-UVA	\$380,000	\$0	\$0	\$0	\$50,000	\$0	\$150,000
Round 5	\$686,985	\$0	\$117,448	\$0	\$239,537	\$0	\$150,000
601 BioTherapeutics-VT-VCU	\$800,000	\$0	\$0	\$0	\$0	\$50,000	\$117,000
602 Propagenix-VCU-UVA	\$425,000	\$0	\$0	\$0	\$175,000	\$80,000	\$0
603 Pulse-ODU-EVMS	\$300,000	\$20,000	\$0	\$280,000	\$0	\$0	\$0
604 SanyalBio-EVMS-GMU	\$100,000	\$0	\$0	\$0	\$0	\$0	\$0
605 Serpin-GMU-VCU	\$400,000	\$0	\$125,000	\$0	\$0	\$125,000	\$0
606 VoltMed-VT-UVA	\$800,000	\$0	\$0	\$0	\$50,000	\$0	\$200,000
Round 6	\$2,825,000	\$20,000	\$125,000	\$280,000	\$225,000	\$255,000	\$317,000
701 BrainBox-VT-UVA	\$500,000	\$0	\$0	\$0	\$90,000	\$0	\$83,010
702 Indivior-VCU-VT-Inova	\$500,000	\$0	\$0	\$0	\$0	\$14,728	\$106,850
703 ReAlta-EVMS-VCU	\$400,000	\$332,352	\$0	\$5,073	\$0	\$0	\$0
Round 7	\$1,400,000	\$332,352	\$0	\$5,073	\$90,000	\$14,728	\$189,860
801 BrightSpecVCU-VT-UVA	\$400,000	\$0	\$0	\$0	\$66,667	\$66,667	\$66,667
802 Continuum-VT-UVA	\$400,000	\$0	\$0	\$0	\$200,000	\$0	\$200,000
803 Embody-ODU-UVA	\$800,000	\$0	\$0	\$198,750	\$198,750	\$0	\$0
804 LifeNet-ODU-EVMS	\$250,000	\$22,500	\$0	\$197,500	\$0	\$0	\$0
805 Serpin-GMU-VCU	\$350,000	\$0	\$150,000	\$0	\$0	\$100,000	\$0
806 WynnVision-VCU-UVA	\$510,000	\$0	\$0	\$0	\$90,000	\$100,000	\$0
Round 8	\$2,710,000	\$22,500	\$150,000	\$396,250	\$555,417	\$266,667	\$266,667
901 AgroSpheres-VT-UVA	\$600,000	\$0	\$0	\$0	\$32,500	\$0	\$201,600
902 BrightSpec-VCU-UVA-VT	\$400,000	\$0	\$0	\$0	\$100,000	\$100,000	\$100,000
903 Ceres-UVA-GMU	\$600,000	\$0	\$95,000	\$0	\$195,000	\$0	\$0
904 Perthera-UVA-EVMS	\$500,000	\$125,000	\$0	\$0	\$162,500	\$0	\$0
Round 9	\$2,100,000	\$125,000	\$95,000	\$0	\$490,000	\$100,000	\$301,600
1001 CytoRecovery-VT-UVA	\$400,000	\$0	\$0	\$0	\$96,000	\$0	\$190,000
1002 InterLeukin-VCU-UVA	\$700,000	\$0	\$0	\$0	\$50,000	\$210,000	\$0
1003 Lytos-UVA-VT	\$500,000	\$0	\$0	\$0	\$92,000	\$0	\$27,000
1004 Monet-GMU-VT	\$400,000	\$0	\$103,125	\$0	\$0	\$0	\$34,375
1005 Rivanna-UVA-VCU	\$800,000	\$0	\$0	\$0	\$88,172	\$23,038	\$0
1006 Tympanogen-EVMS-VCU	\$500,000	\$25,220	\$0	\$0	\$0	\$137,260	\$0
Round 10	\$3,300,000	\$25,220	\$103,125	\$0	\$326,172	\$370,298	\$251,375
1101 Contraline-UVA-VCU	\$600,000	\$0	\$0	\$0	\$32,400	\$32,400	\$0
1102 ISOThrive-GMU-EVMS-UVA	\$800,000	\$5,000	\$0	\$0	\$5,000	\$0	\$0
1103 Meru-VCU-ODU	\$700,000	\$0	\$0	\$106,700	\$0	\$127,500	\$0
Round 11	\$2,100,000	\$5,000	\$0	\$106,700	\$37,400	\$159,900	\$0
Running disbursement totals:	\$21,391,214	\$935,588	\$811,938	\$1,623,523	\$3,218,563	\$1,929,377	\$2,356,171

C.2 Fiscal Year 2021: Independent Auditor's Report



Certified Public Accountants

September 27, 2021

Board of Directors and Management
Virginia Biosciences Health Research Corporation
c/o Virginia Economic Development Partnership
901 E. Cary Street, Suite 900
Richmond, Virginia 23219

We have audited the financial statements of Virginia Biosciences Health Research Corporation (the Corporation) for the year ended June 30, 2021, and have issued our report thereon dated September 24, 2021.

Current audit standards require the auditor to communicate certain matters to keep those charged with governance adequately informed about matters related to the financial statement audit that are, in our professional judgment, significant and relevant to the responsibilities of those charged with governance in overseeing the financial reporting process.

The following summarizes those communications:

The Auditor's Responsibility Under Generally Accepted Auditing Standards

As stated in our engagement letter dated July 13, 2021, which was signed on your behalf by Dr. David Cifu, Board President, our responsibility, as described by professional standards, is to express an opinion about whether the financial statements prepared by management with your oversight are fairly presented, in all material respects, in conformity with accounting principles generally accepted in the United States of America. Our audit of the financial statements does not relieve you or management of your responsibilities.

Planned Scope and Timing of the Audit

We performed the audit according to the planned scope and timing previously communicated to you through the engagement letter and other communications about planning matters.

-2-

Board of Directors and Management

September 27, 2021

Significant Audit Findings

- *Qualitative Aspects of Accounting Practices*

Management has the ultimate responsibility for the appropriateness of the accounting policies used by the Corporation. The significant accounting policies used by the Corporation are described in Note 1 to the financial statements. The Corporation did not adopt any significant new accounting policies nor have there been any changes in existing significant accounting policies during the current period. We did not identify any significant or unusual transactions or significant accounting policies in controversial or emerging areas for which there is a lack of authoritative guidance or consensus. We did not discuss with management of any alternative treatments within generally accepted accounting principles for accounting policies and practices related to material items during the current audit period. There are no significant transactions that have been recognized in the financial statements in a different period than when the transaction occurred.

Accounting estimates are an integral part of the financial statements prepared by management and are based upon management's current judgment. The process used by management encompasses their knowledge and experience about past and current events, and certain assumptions about future events. Certain accounting estimates are particularly sensitive because of their significance to the financial statements and because of the possibility that future events affecting them may differ significantly from those expected. The most sensitive estimate is summarized below. We evaluated the key factors and assumptions used to develop the estimate in determining that it is reasonable in relation to the financial statements taken as a whole.

Allocation of Functional Expenses

Current accounting standards require organizations to report expenses by their functional classification, such as by their programs and supporting activities. Costs common to multiple functions have been allocated based on activity reports prepared by key employees. Based on these reports, the Corporation has estimated the President and CEO's salary to consist of 90% for program services and 10% for management and general activities, and the VP of Operations' salary to consist of 95% for program services and 5% for management and general activities.

The disclosures in the financial statements are neutral, consistent, and clear. Certain financial statement disclosures are particularly sensitive because of their significance to financial statement users.

- *Difficulties Encountered in Performing the Audit*

We encountered no significant difficulties in dealing with management in performing and completing our audit.

-3-

Board of Directors and Management

September 27, 2021

- *Corrected and Uncorrected Misstatements*

Professional standards require us to accumulate all known and likely misstatements identified during the audit, other than those that are trivial, and communicate them to the appropriate level of management. There were no audit adjustments proposed by us and made by the Corporation.

We also accumulate uncorrected misstatements, which are determined to be immaterial to the financial statements taken as a whole. We did not identify any uncorrected misstatements.

- *Disagreements with Management*

For purposes of this letter, professional standards define a disagreement with management as a financial accounting, reporting, or auditing matter, whether or not resolved to our satisfaction, that could be significant to the financial statements or to the auditor's report. We encountered no disagreements with management during the course of our audit.

- *Management Representations*

We have requested certain representations from management that are included in the management representation letter dated September 24, 2021.

- *Management Consultations with Other Independent Accountants*

In some cases, management may decide to consult with other accountants about auditing and accounting matters, similar to obtaining a "second opinion" on certain situations. If a consultation involves application of an accounting principle to the Corporation's financial statements or a determination of the type of auditor's opinion that may be expressed on those statements, our professional standards require the consulting accountant to check with us to determine that the consultant has all of the relevant facts. To our knowledge, there were no such consultations with other accountants.

- *Other Audit Findings or Issues*

We generally discuss a variety of matters, including the application of accounting principles and auditing standards, with management each year prior to retention as the Corporation's auditor. However, these discussions occurred in the normal course of our professional relationship, and our responses were not a condition to our retention.

This report is intended solely for the information and use of the Board of Directors and management of the Virginia Biosciences Health Research Corporation, and is not intended to be, and should not be, used by anyone other than these specified parties.

Mitchell Wiggins



CERTIFIED PUBLIC ACCOUNTANTS

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst

Financial Statements

June 30, 2021 and 2020

RICHMOND: 804-282-6000

TRI-CITIES: 804-733-5566

www.mwcpa.com

***Virginia Biosciences Health
Research Corporation d/b/a Virginia
Catalyst***

Table of Contents

	<i>Page</i>
<i>Independent Auditor's Report</i>	<i>1 - 2</i>
<i>Financial Statements</i>	
<i>Statements of financial position</i>	<i>3</i>
<i>Statements of activities</i>	<i>4</i>
<i>Statements of functional expenses</i>	<i>5</i>
<i>Statements of cash flows</i>	<i>6</i>
<i>Notes to financial statements</i>	<i>7 - 12</i>



Certified Public Accountants

Independent Auditor's Report

Board of Directors

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst
Richmond, Virginia

Report on the Financial Statements

We have audited the accompanying financial statements of Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst, which comprise the statement of financial position as of June 30, 2021 and 2020, the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Mitchell Wiggins

Richmond, Virginia
September 24, 2021

Virginia Biosciences Health Research Corporation
d/b/a Virginia Catalyst
Statements of Financial Position
June 30, 2021 and 2020

	2021	2020
Assets		
Cash and cash equivalents	\$ 9,960,465	\$ 3,970,580
Pledges receivable		
Member universities	300,000	350,000
Commonwealth of Virginia	3,750,000	7,500,000
Total assets	\$ 14,010,465	\$ 11,820,580
Liabilities and Net Assets		
Liabilities		
Accounts payable	\$ 152,728	\$ 235,755
Net Assets		
Net assets without donor restrictions	5,107,737	4,084,825
Net assets with donor restrictions	8,750,000	7,500,000
Total net assets	13,857,737	11,584,825
Total liabilities and net assets	\$ 14,010,465	\$ 11,820,580

See Notes to Financial Statements

Virginia Biosciences Health Research Corporation
d/b/a Virginia Catalyst
Statements of Activities
Years Ended June 30, 2021 and 2020

	2021			2020		
	Net Assets Without Donor	Net Assets With Donor Restrictions	Total	Net Assets Without Donor	Net Assets With Donor Restrictions	Total
Revenue						
Contributions, Virginia General Assembly						
Program support	\$ -	\$ 5,000,000	\$ 5,000,000	\$ -	\$ 6,500,000	\$ 6,500,000
General and administrative support	-	-	-	-	1,000,000	1,000,000
Contributions, Member Universities						
College of William & Mary	-	-	-	50,000	-	50,000
Eastern Virginia Medical School	50,000	-	50,000	50,000	-	50,000
George Mason University	50,000	-	50,000	50,000	-	50,000
Old Dominion University	50,000	-	50,000	50,000	-	50,000
University of Virginia	50,000	-	50,000	50,000	-	50,000
Virginia Commonwealth University	50,000	-	50,000	50,000	-	50,000
Virginia Polytechnic Institute and State University	50,000	-	50,000	50,000	-	50,000
Interest income	132	-	132	3,248	-	3,248
	<u>300,132</u>	<u>5,000,000</u>	<u>5,300,132</u>	<u>353,248</u>	<u>7,500,000</u>	<u>7,853,248</u>
Net Assets Released from Restrictions						
Satisfaction of time restrictions	3,750,000	(3,750,000)	-	3,750,000	(3,750,000)	-
Total support and revenues	<u>4,050,132</u>	<u>1,250,000</u>	<u>5,300,132</u>	<u>4,103,248</u>	<u>3,750,000</u>	<u>7,853,248</u>
Expenses						
Program services	2,931,894	-	2,931,894	3,562,446	-	3,562,446
Management and general	95,326	-	95,326	78,978	-	78,978
Total expenses	<u>3,027,220</u>	<u>-</u>	<u>3,027,220</u>	<u>3,641,424</u>	<u>-</u>	<u>3,641,424</u>
Change in net assets	<u>1,022,912</u>	<u>1,250,000</u>	<u>2,272,912</u>	<u>461,824</u>	<u>3,750,000</u>	<u>4,211,824</u>
Net assets, beginning	<u>4,084,825</u>	<u>7,500,000</u>	<u>11,584,825</u>	<u>3,623,001</u>	<u>3,750,000</u>	<u>7,373,001</u>
Net assets, ending	<u>\$ 5,107,737</u>	<u>\$ 8,750,000</u>	<u>\$ 13,857,737</u>	<u>\$ 4,084,825</u>	<u>\$ 7,500,000</u>	<u>\$ 11,584,825</u>

See Notes to Financial Statements

Virginia Biosciences Health Research Corporation
d/b/a Virginia Catalyst
Statements of Functional Expenses
Years Ended June 30, 2021 and 2020

	2021			2020		
	Program Services	Management and General	Total	Program Services	Management and General	Total
Accounting services	\$ -	\$ 35,829	\$ 35,829	\$ -	\$ 34,180	\$ 34,180
Conferences	-	-	-	535	-	535
Consulting services	6,000	-	6,000	2,238	-	2,238
Employee benefits	35,891	1,889	37,780	-	-	-
Grant expenses	2,604,200	-	2,604,200	3,239,164	-	3,239,164
Legal expenses	-	27,262	27,262	-	11,575	11,575
Marketing and promotion	2,550	-	2,550	2,550	-	2,550
Meals and entertainment	-	-	-	388	-	388
Memberships and sponsorships	18,750	-	18,750	25,000	-	25,000
Miscellaneous	-	-	-	338	510	848
Office expenses	-	970	970	-	522	522
Parking	-	935	935	-	1,961	1,961
Payroll taxes	15,751	1,442	17,193	17,274	1,498	18,772
Occupancy	-	2,831	2,831	-	3,000	3,000
Salaries and wages	248,752	23,619	272,371	273,522	24,922	298,444
Telephone	-	549	549	-	810	810
Travel and lodging	-	-	-	1,437	-	1,437
	\$ 2,931,894	\$ 95,326	\$ 3,027,220	\$ 3,562,446	\$ 78,978	\$ 3,641,424

See Notes to Financial Statements

Virginia Biosciences Health Research Corporation
d/b/a Virginia Catalyst
Statements of Cash Flows
Years ended June 30, 2021 and 2020

	2021	2020
Cash Flows from Operating Activities		
Change in net assets	\$ 2,272,912	\$ 4,211,824
<i>Adjustments to reconcile change in net assets to net cash and cash equivalents provided by operating activities</i>		
<i>Changes in operating assets</i>		
Pledges receivables	3,800,000	(3,750,000)
<i>Changes in operating liabilities</i>		
Accounts payable	(83,027)	(374,346)
Net cash and cash equivalents provided by operating activities	5,989,885	87,478
Cash and cash equivalents, beginning	3,970,580	3,883,102
Cash and cash equivalents, ending	\$ 9,960,465	\$ 3,970,580

See Notes to Financial Statements

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst

Notes to Financial Statements

June 30, 2021 and 2020

Note 1. Nature of Organization and Summary of Significant Accounting Policies

Nature of organization

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst (the Corporation) was organized as a not-for-profit corporation in 2013 and is operated for educational and research purposes. The mission of the Corporation is to foster life sciences research at universities located within the Commonwealth of Virginia by providing resources for partnering between public and private institutions and not-for-profit universities. The five founding institutions are Eastern Virginia Medical School, George Mason University, University of Virginia, Virginia Commonwealth University, and Virginia Polytechnic Institute and State University. Old Dominion University was admitted in December 2013 and College of William & Mary was admitted in October 2016 and exited in July 2020. Research is to be centered in three focus areas: bioinformatics and medical informatics, point of care diagnostics, and drug discovery and delivery.

A summary of the Corporation's significant accounting policies follows:

Financial statement presentation

Under current accounting standards, the Corporation is required to report information regarding its financial position and activities according to two classes of assets: net assets without donor restrictions and net assets with donor restrictions. The net asset classes are summarized as follows:

Net assets without donor restrictions include board designated and other funds without donor restrictions. The funds without donor restrictions include revenue and expenses used currently for the general operations of the Corporation. Contributions that are with donor restrictions are reported as increases in net assets without donor restrictions if the donor restrictions expire in the fiscal year in which the contributions are recognized.

Net assets with donor restrictions include contributions restricted by donor designation or time restrictions and are reported as increases in net assets with donor restrictions. When a restriction expires either with the passage of time or by actions of the Corporation, contributions with donor restrictions are released and reclassified to net assets without donor restrictions. Net assets with donor restrictions consist of pledged contributions due in future years.

Cash and cash equivalents

The Corporation considers all highly liquid investments with an initial maturity of three months or less to be cash equivalents.

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst
Notes to Financial Statements
June 30, 2021 and 2020

Note 1. Nature of Organization and Summary of Significant Accounting Policies (continued)

Pledges receivable

Pledges are recognized when the donor makes a promise to give to the Corporation that is, in substance, unconditional. Contributions that are restricted by the donor are reported as increases in net assets with donor restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

Contributions

Contributions, including unconditional promises to give, are recognized when received. All contributions are reported as increases in net assets without donor restrictions unless use of the contributed assets is specifically restricted by the donor. Amounts received that are restricted by the donor to use in future periods or for specific purposes are reported as increases in net assets with donor restrictions. Unconditional promises with payments due in future years have an implied restriction to be used in the year the payment is due, and therefore are reported as restricted until the payment is due, unless the contribution is clearly intended to support activities of the current fiscal year. Conditional promises, such as matching grants, are not recognized until they become unconditional, that is, until all conditions on which they depend are substantially met.

Expense recognition and allocation

The cost of providing the Corporation's programs and other activities is summarized on a functional basis in the statement of activities and statement of functional expenses. Expenses that can be identified with a specific program or support service are charged directly to that program or support service. Costs common to multiple functions have been allocated among the various functions benefited using a reasonable allocation method that is consistently applied, as follows:

- Salaries and wages, and payroll taxes are allocated based on activity reports prepared by key personnel.

Every three years, or more often when new programs are added, the bases on which costs are allocated are evaluated.

General and administrative expenses include those costs that are not directly identifiable with any specific program, but which provide for the overall support and direction of the Corporation.

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst
Notes to Financial Statements
June 30, 2021 and 2020

Note 1. Nature of Organization and Summary of Significant Accounting Policies (continued)

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Income taxes

The Corporation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is not classified as a Private Foundation.

The Financial Accounting Standards Board issued guidance on accounting for uncertainty in income taxes. Management evaluated the Corporation's tax positions and concluded that the Corporation had taken no uncertain tax positions that require adjustment to the financial statements to comply with the provisions of this guidance.

The Corporation includes penalties and interest assessed by income taxing authorities in management and general expenses. The Corporation did not have penalties and interest relating to income taxes for the years ended June 30, 2021 and 2020.

Classification of transactions

All revenues and net gains are reported as increases in net assets without donor restrictions in the statement of activities unless the donor specified the use of the related resources for a particular purpose or in a future period. All expenses and net losses are reported as decreases in net assets without donor restrictions.

Note 2. Concentration of Credit Risk

The Corporation maintains its cash balances in one financial institution and the accounts, at times, may exceed federally insured limits. As of June 30, 2021 and 2020, the cash in the bank exceeded the federally insured limit by \$9,710,465 and \$3,720,580, respectively. The Corporation maintains its funds at a national bank and feels that the risk of loss is minimal.

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst**Notes to Financial Statements****June 30, 2021 and 2020****Note 3. Concentration of Revenue**

For the year ended June 30, 2021 and 2020, the Corporation received the majority of its funding from appropriations approved by the General Assembly of the Commonwealth of Virginia. Funding is typically granted for a two-year period as stipulated in the budget of the Commonwealth. These funds were net assets with donor restrictions and are released based on time. The funding is used to support the mission of the Corporation to capture and perform research in biosciences, as well as promote the development of bioscience infrastructure tools which can be used to facilitate additional research activities.

Note 4. Pledged Contributions Receivable

The Corporation's policy is to record only written pledged contributions receivable. Management estimates that no allowance for doubtful accounts is required.

The pledged contributions receivable as of June 30, 2021 and 2020, are as follows:

	2021	2020
Commonwealth of Virginia	\$3,750,000	\$7,500,000
College of William & Mary	-	50,000
Eastern Virginia Medical School	50,000	50,000
George Mason University	50,000	50,000
Old Dominion University	50,000	50,000
University of Virginia	50,000	50,000
Virginia Commonwealth University	50,000	50,000
Virginia Polytechnic Institute and State University	50,000	50,000
	<u>\$4,050,000</u>	<u>\$7,850,000</u>
	2021	2020
Amounts expected to be received in:		
Less than one year	\$4,050,000	\$4,100,000
One to five years	-	3,750,000
	<u>\$4,050,000</u>	<u>\$7,850,000</u>

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst**Notes to Financial Statements****June 30, 2021 and 2020****Note 5. Liquidity and Availability**

Financial assets available for general expenditure that is, without donor or other restrictions limiting their use, within one year of June 30, 2021 and 2020 are:

	2021	2020
Financial assets at year-end:		
Cash and cash equivalents	\$ 9,960,465	\$ 3,970,580
Pledges receivable	4,050,000	7,850,000
Total financial assets	14,010,465	11,820,580
Less financial assets held to meet donor-imposed restrictions:		
Purpose restricted net assets (Note 6)	(5,000,000)	-
Less board designations:		
Operating reserves	(180,000)	(180,000)
Pledges due in one to five years	-	(3,750,000)
Financial assets available to meet general expenditures over the next twelve months	<u>\$ 8,830,465</u>	<u>\$ 7,890,580</u>

The board designation for operation reserves is in place to ensure the Corporation's ongoing and future viability to withstand the impact of economic downturns and invest in strategic opportunities. The Corporation only holds liquid assets consisting of cash and cash equivalents. The Corporation uses a budgeting process to manage its cash flow and liquidity needs.

Note 6. Net Assets with Donor Restrictions

As of June 30, 2021 and 2020, net assets with donor restrictions are available for the following purposes or periods:

	2021	2020
Purpose restrictions, available for spending:		
Covid-19 Research	\$ 5,000,000	\$ -
Time restrictions:		
Contributions receivable, which are unavailable for spending until due	3,750,000	7,500,000
Total net assets with donor restrictions	<u>\$ 8,750,000</u>	<u>\$ 7,500,000</u>

Virginia Biosciences Health Research Corporation d/b/a Virginia Catalyst
Notes to Financial Statements
June 30, 2021 and 2020

Note 7. Covid-19

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it be a pandemic. COVID-19 and actions to mitigate it have had, and are expected to continue to have, an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Corporation operates. The extent to which the COVID-19 pandemic may impact operating results, financial condition, and cash flows will depend on future developments, which are highly uncertain and cannot be predicted as of the date of this report. The Corporation is adequately capitalized and continues to evaluate operational impacts and implement mitigation tactics where possible and necessary.

Note 8. Subsequent Events

Management has evaluated subsequent events through September 24, 2021, the date which the financial statements were available for issue.

C.3 Fiscal Year 2022: Pro Forma Budget

Virginia Biosciences Health Research Corporation
Fiscal Year 2022 Budget

	Fiscal Year 2021			Fiscal Year 2022
	Budget	Actual	Over (Under)	Proposed Budget
Income				
400500 - Program support	3,250,000	5,000,000		6,500,000
401000 - General and admin support	500,000	-		1,000,000
400000 - Virginia General Assembly	3,750,000	5,000,000	1,250,000	7,500,000
400000 - Catalyst Conference				
410000 - Member University Contributions				
411000 - Eastern Va Medical School	50,000	50,000	-	50,000
412500 - George Mason University	50,000	50,000	-	50,000
413100 - Old Dominion University	50,000	50,000	-	50,000
413000 - University of Virginia	50,000	50,000	-	50,000
412000 - Virginia Commonwealth	50,000	50,000	-	50,000
410500 - Virginia Tech	50,000	50,000	-	50,000
Total 410000 - Member University Contributions	300,000	300,000	-	300,000
440000 - Other Sources (Interest income)	-	132	132	-
Total Income	4,050,000	5,300,132	1,250,132	7,800,000
Expenses				
Program Expenses:				
510000 - Collaborative Grant Program- Industry/Research Universities	5,183,278			-
510600 Round 6		50,000		-
510700 Round 7		-		-
510800 Round 8		5,000		10,000
510900 Round 9		260,000		-
511000 Round 10		1,719,000		520,000
511100 Round 11		570,200		1,529,800
511200 Round 12		-		1,000,000
511300 Round 13		-		250,000
C1901 PBM-UVA		-		345,000
C1902 ReAlta-ODU		-		1,356,000
C1903-Serpin-UVA		-		500,000
Total 5120 Collaborative Grant Program	5,183,278	2,604,200	-	5,510,800
590000 - Support and development				
590100 - Salaries and Benefits				
590110 - Salaries and Wages	276,000	272,371	(3,629)	355,000
590120 - Payroll Taxes	22,950	17,193		27,158
590130 - Other Benefits	24,000	37,780	13,780	24,402
Total 590000 - Salaries and Benefits	322,950	327,344	10,151	406,560
590200 - Program development				
590210 - Advertising/press releases	2,500	2,550	50	2,500

Virginia Biosciences Health Research Corporation
Fiscal Year 2022 Budget

	Fiscal Year 2021			Fiscal Year 2022
	Budget	Actual	Over (Under)	Proposed Budget
590220 - Marketing and promotion	-	-	-	-
590230 - Conferences	4,000	-	(4,000)	7,500
590240 - Meals and Entertainment	1,000	-	(1,000)	1,000
590250 - Memberships and sponsorships	25,000	18,750	(6,250)	20,000
590280 - Other program development exp.	800	-	(800)	-
590270 - Consulting fees		6,000	6,000	-
590260 - Travel and lodging	4,000	-	(4,000)	2,000
Total 590200 - Program development	37,300	27,300	(10,000)	33,000
Total Support and development	360,250	354,644	151	439,560
TOTAL PROGRAM EXPENSES	5,543,528	2,958,844	151	5,950,360
600000 - General and administrative				
601000 - Salaries and wages 20%		-	-	-
600200 - Salary administrative assistant		-	-	-
600300 - Payroll Taxes		-	-	-
604000 - Accounting services	24,000	24,554	554	22,469
606000 - Audit and tax returns	10,000	11,275	1,275	12,550
608000 - Board of Directors Expense	1,000	-	(1,000)	1,000
609000 - Memberships and sponsorships			-	-
620000 - Mileage			-	-
610000 - Exhibit Booth		-	-	-
611000 - Conferences		-	-	-
615000 - Dues and Subscriptions		545	545	545

Virginia Biosciences Health Research Corporation
Fiscal Year 2022 Budget

	Fiscal Year 2021			Fiscal Year 2022
	Budget	Actual	Over (Under)	Proposed Budget
612000 - Web Site	400	425	25	425
616000 - Insurance	500		(500)	500
617000 - Legal Expenses	18,000	27,262	9,262	20,000
629000 - Miscellaneous operating expense			-	-
618000 - Office and Computer Supplies	1,000		(1,000)	1,000
619000 - Rent	4,000	2,831	(1,169)	3,474
621000 - Parking	1,000	935	(65)	1,140
622000 - Postage	200	-	(200)	100
624000 - Telephone	1,250	549	(701)	1,000
Total 600000 - General and administrative	61,350	68,375	7,025	64,203
Total Expenses	5,604,878	3,027,219	7,176	6,014,562
NET INCOME	(1,554,878)	2,272,912	1,242,956	1,785,438

Catalyst Conference

Revenue/Expenses 250 Attendees

75,000

Revenue/Expenses 150 Attendees

45,000

Appendix D: Grant Funding Rounds

D.1 Summary of Awarded Projects to Date

Grant Round 1 – December 2013

Virginia Polytechnic Institute and State University
Virginia Commonwealth University

BioTherapeutics, Inc.

Blacksburg, VA

<https://www.biotherapeuticsinc.com/>

Company status: active

Created Spin-off, public traded: **Landos BioPharma**

<https://landosbiopharma.com/about-us/our-company/>

Development of novel anti-inflammatory drugs

University of Virginia
George Mason University

HemoShear Therapeutics, LLC

Charlottesville, VA

<https://www.hemoshear.com/>

Company status: active

Commercialization of a human tumor microenvironment system for pharmaceutical cancer drug discovery and development

Virginia Polytechnic Institute and State University
University of Virginia

FirstString Research, Inc.

Roanoke, VA; Headquarters Mt. Pleasant, SC

<https://firststringresearch.com/>

Company status: active

Novel regenerative drug

University of Virginia
Virginia Commonwealth University

Cavion (formerly Tau Therapeutics)

Charlottesville, VA and Cambridge, MA

<https://cavionpharma.com/>

Company status: active

Determining the optimal dosing schedule for the commercialization of mibefradil in front-line glioblastoma

Grant Round 2 – March 2014

**University of Virginia
Virginia Commonwealth University**

Neoantigenics, Inc.
Charlottesville, VA
[https://www.linkedin.com/company/neoantigenics-inc./](https://www.linkedin.com/company/neoantigenics-inc/)

Company status: inactive

UVA-VCU partnership to develop radioimmunotherapeutic and imaging agents to a unique cell-surface target relevant for multiple human cancers

**Virginia Commonwealth University
University of Virginia**

Gencia, LLC
Charlottesville, VA
<http://genciabiotech.com/>

Company status: inactive

Reversing bioenergetic deficits and improving cognitive function in Alzheimer's Disease

**Virginia Polytechnic Institute and State University
University of Virginia**

SphynKx Therapeutics, LLC
Charlottesville, VA
<https://www.linkedin.com/company/sphynkx-therapeutics/>

Company status: inactive

Lead optimization of a SphK2 inhibitor for the treatment of CKD

**Eastern Virginia Medical School
University of Virginia**

LifeNet Health
Global Headquarters: Virginia Beach, VA
<https://www.lifenethealth.org/>

Company status: active

Enhancement of healing in diabetic wounds using a decellularized dermal matrix

Grant Round 3 – August 2014

**Virginia Commonwealth University
Old Dominion University**

Ultrasonic Probe, LLC
Glen Allen, VA

Company status: inactive

Ultrasonographic probe

**Virginia Polytechnic Institute and State University
University of Virginia**

PhenoCHIP Technologies, LLC

(formerly Proteo Biosciences)

Blacksburg, VA

<https://govtribe.com/vendor/phenochip-technologies-llc-blacksburg-va>

Company status: inactive

PhenoCHIP-phenotype-based cell hierarchy and isolation platform

**Old Dominion University
Eastern Virginia Medical School**

OncoSec Medical, Inc

San Diego, CA and Pennington, NJ

<https://oncosec.com/>

Company status: active

Biomarker-driven optimization of IL-12 gene electrotransfer for the treatment of melanoma

Grant Round 4 – August 2015

**Virginia Polytechnic Institute and State University
University of Virginia**

FirstString Research, Inc.

Roanoke, VA and Mt. Pleasant, SC

<https://firststringresearch.com/>

Company status: active

Clinical trial of new drug in dogs to treat brain cancer in humans

**Old Dominion University
Eastern Virginia Medical School**

Embody, LLC

Norfolk, VA

<https://embody-inc.com/>

Company status: active

Nanofabrication of tissue scaffolds

**Virginia Polytechnic Institute and State University
Virginia Commonwealth University**

BioTherapeutics, Inc.

Blacksburg, VA

<https://www.biotherapeuticsinc.com/>

Company status: active

Created Spin-off, public traded: **Landos BioPharma**

<https://landosbiopharma.com/about-us/our-company/>

Optimizing oral delivery of BT-11 as a clinical candidate for treating inflammatory bowel disease

**Virginia Commonwealth University
University of Virginia**

BrightSpec
Charlottesville, VA
<http://brightspec.com/>

Company status: active

Three wave mixing technique for chiral analysis in continuous process manufacturing

**George Mason University
Virginia Polytechnic Institute and State University**

Ceres Nanosciences, Inc.
Manassas, VA
<http://www.ceresnano.com/>

Company status: active

Nanotrap® tick-panel test development

Grant Round 5 – December 2015

**University of Virginia
George Mason University
Yale University**

Cavion
Charlottesville, VA and Cambridge, MA
<https://cavionpharma.com/>

Company status: active

Development of a biomarker assay and protocol for the commercialization of mibefradil dihydrochloride as a first-line treatment for glioblastoma

**Virginia Polytechnic Institute and State University
University of Virginia**

VoltMed, Inc.
Blacksburg, VA
<https://voltmeddevices.com/>

Company status: active

INSPIRE to fight brain cancer

Grant Round 6 – October 2016

**Virginia Polytechnic Institute and State University
University of Virginia
VoltMed, Inc.**

Company status: active

Blacksburg, VA
<https://www.linkedin.com/company/voltmed-inc./>

Commercialization of INSPIRE brain cancer treatment

**Virginia Polytechnic Institute and State University
Virginia Commonwealth University**

BioTherapeutics, Inc.

Blacksburg, VA

<https://www.biotherapeuticsinc.com/>

Company status: active

Development of BT-11: First-in-class oral therapeutic for Inflammatory Bowel Disease

**George Mason University
Virginia Commonwealth University**

Serpin Parma, LLC

Manassas, VA

<http://www.serpinpharma.com/>

Company status: active

Novel and potent anti-inflammatory drug with cardio-protective effects to treat myocardial injury and prevent heart failure

**Eastern Virginia Medical School
George Mason University**

Sanyal Biotechnology, LLC

Virginia Beach, VA

<https://www.sanyalbio.com/>

Company status: active

Merged with: MetabAxis, Richmond, VA

<https://metabaxis.com/>

Accelerating the commercialization of the Diamond™ mouse model of Nonalcoholic Steatohepatitis

**Old Dominion University
Eastern Virginia Medical School**

Pulse Biosciences, Inc.

Hayward, CA

<http://pulsebiosciences.com/>

Company status: active

Translational research with nanosecond pulsed electric fields for immuno-oncology applications

**Virginia Commonwealth University
University of Virginia**

Propagenix, Inc.

Rockville, MD

<http://www.propagenix.com/>

Company status: active

Bioengineering for the therapeutic delivery of massively expanded islet-derived human beta-cells

Grant Round 7 – July 2017

**Virginia Commonwealth University,
Virginia Polytechnic Institute and State University
Inova
George Mason University**

Indivior, PLC
Richmond, VA
<http://indivior.com/>

Company status: active

Novel Preventive Treatment Paradigm to Change the Standard of Care for Those Who Recover from Opioid Overdose

**Virginia Polytechnic Institute and State University
University of Virginia
Carilion**

BRAINBox Solutions
(Parent company: ImmunArray)
Richmond, VA
<https://brainboxinc.com/>

Company status: active

Virginia Brain Injury Diagnosis and Monitoring Initiative

**Eastern Virginia Medical School
Virginia Commonwealth University**

ReAlta Life Sciences, LLC
Norfolk, VA
<https://www.sbir.gov/sbirsearch/detail/1430737>

Company status: active

Development of peptide inhibitor of complement C1 as treatment for neonatal hypoxic-ischemic encephalopathy

Grant Round 8 – May 2018

**Old Dominion University
University of Virginia**

Embody, LLC
Vienna, VA
<https://govtribe.com/vendor/embody-llc-vienna-va>

Company status: active

Biofabrication of Regenerative Musculoskeletal Therapeutics

**Virginia Polytechnic Institute and State University
University of Virginia**

Continuum Biosciences, Inc.

Company status: active

Blacksburg, VA

<https://continuumbio.com/>

Development and commercialization of mitochondrial uncouplers

**Virginia Commonwealth University
University of Virginia
Virginia Polytechnic Institute and State University**

BrightSpec, Inc.

Company status: active

Charlottesville, VA

<http://brightspec.com/>

A major new chiral analysis technique for new drug discovery, development, and process control

**Virginia Commonwealth University
George Mason University**

Serpin Pharma, LLC

Company status: active

Manassas, VA

<http://www.serpinpharma.com/>

Novel anti-inflammatory drug: strong neuroprotective properties for treat of traumatic brain injury

**Old Dominion University
Eastern Virginia Medical School**

LifeNet Health

Company status: active

Global Headquarters: Virginia Beach, VA

<https://www.lifenethealth.org/>

Tissue preparations for therapeutic use in cardiovascular applications

**Virginia Commonwealth University
University of Virginia**

WynnVision, LLC

Company status: active

Richmond, VA

<https://www.wynnvision.com/>

Preventing Catheter Associated Infections

Grant Round 9 – May 2019

**Virginia Polytechnic Institute and State University
University of Virginia**

AgroSpheres, Inc.

Company status: active

Charlottesville, VA

<https://www.agrospheres.com/>

AgroSpheres-Enabled Biological Fungicide

**Virginia Commonwealth University
University of Virginia
Virginia Polytechnic Institute and State University**

BrightSpec, Inc.

Company status: active

Charlottesville, VA

<http://brightspec.com/>

Rapid Drug Development Using Molecular Rotational Resonance (MRR) for Structure Analysis

**University of Virginia
George Mason University**

Ceres Nanosciences, Inc.

Company status: active

Manassas, VA

<https://www.ceresnano.com/>

Nanotrap® Liquid Biopsy Collection Device (LBC) for Cancer Diagnostics

**University of Virginia
Eastern Virginia Medical School**

Perthera, Inc

Company status: active

McLean, VA

<https://perthera.com/>

Implementation and Clinical Impact of a Next Generation Precision Oncology Platform

Grant Round 10 – January 2020

**Virginia Polytechnic Institute and State University
University of Virginia**

CytoRecovery, Inc.

Company status: active

Blacksburg, VA

<https://www.cytorecovery.com/>

Microsystem for Label-Free Separation and Recovery of Tumor-Associated Cells from Biopsies for Precision Medicine

**Virginia Commonwealth University
University of Virginia**

InterLeukin Combinatorial Therapies, Inc. **Company status: active**
Richmond, VA
<https://aim-hiaccelerator.org/ilct/>

Commercializing a Novel Treatment for Metastatic Cancers

**University of Virginia
Virginia Polytechnic Institute and State University**

Lytos Technologies, LLC **Company status: active**
Charlottesville, VA
<https://www.lytotech.com/>

Design and Implementation of Green, Enzymatic Biofungicides for Pre- and Post-Harvest Crop Protection

**George Mason University
Virginia Polytechnic Institute and State University**

Monet Pharmaceuticals **Company status: active**
Manassas, VA
<https://opengovus.com/sam-entity/116975682>

Protein Painting of PD-1/PD-L1 for the Discovery of New Immune Checkpoint Inhibitors for the Treatment of Lung Cancer and Brain Metastasis

**University of Virginia
Virginia Commonwealth University**

RIVANNA Medical, LLC **Company status: active**
Charlottesville, VA
<https://rivannamedical.com/>

Automated 3D spinal navigation system for bedside lumbar puncture procedures

**Eastern Virginia Medical School
Virginia Commonwealth University**

Tympanogen, Inc. **Company status: active**
Richmond, VA
<http://www.tympanogen.com/>

Development of an applicator and training simulator for a gel patch for nonsurgical eardrum repair

Grant Round 11 – October 2020

**University of Virginia
Virginia Commonwealth University**

Contraline, Inc.
Charlottesville, VA
<http://www.contraline.com/>

Company status: active

Clinical Translation of a Male Contraceptive Procedure

**George Mason University
Eastern Virginia Medical School**

ISOThrive, Inc.
Healdsburg, CA
<https://pharma.iso thrive .com/>

Company status: active

Clinical Trial of Maltosyl-isomaltooligosaccharide (MIMO) to treat Gastroesophageal Reflux Disease (GERD), a Dysbiotic Infectious Disease, and its effect on Dysbiosis-Induced Carcinogenic Inflammation

**Virginia Commonwealth University
Old Dominion University**

Meru Biotechnologies, Inc.
Richmond, VA
<https://www.merubio.com/>

Company status: active

Innovative Bioanalytical Instrument for Improving Drug Discovery

[remainder of this page intentionally left blank]

D.2 Summary of Economic Returns to Date

Collaborators	Amount of Grant Award	Matching Funds	Follow on Funding	Job Creation (FTE)
---------------	-----------------------	----------------	-------------------	--------------------

Grand Round 1 - December 2013

VT, VCU	BioTherapeutics Inc. Blacksburg, VA	\$400,000	\$400,000	\$10,000,000	15
UVA, VCU	Tau Therapeutics (Cavion LLC) Charlottesville, VA	\$200,000	\$238,000	\$26,100,000	2.5
VT, UVA	First String Research Roanoke, VA and Mt. Pleasant, SC	\$200,000	\$1,000,000	\$3,000,000	10
UVA, GMU	HemoShear LLC Charlottesville, VA	\$450,000	\$800,000	\$14,000,000	12
Subtotal Round 1		\$1,250,000	\$2,438,000	\$53,100,000	39.5

Grand Round 2 - March 2014

VCU, UVA	Gencia, LLC Charlottesville, VA	\$400,000	\$400,000	\$8,800,000	2
UVA, VCU	Neoantigenics LLC Charlottesville, VA	\$348,729	\$2,000,000	\$3,000,000	1
VT, UVA	SphynKx Therapeutics Charlottesville, VA	\$400,000	\$400,000	\$150,000	4
EVMS, UVA	LifeNet Health Virginia Beach, VA	\$255,000	\$255,000	\$5,000	3
Subtotal Round 2		\$1,403,729	\$3,055,000	\$11,955,000	10

Grand Round 3 - August 2014

VT, UVA	PhenoCHIP Blacksburg, VA	\$270,000	\$386,000	\$450,000	5
ODU, EVMS	OncoSec Medical San Diego, CA	\$585,000	\$2,750,000	\$8,700,000	3.5
VCU, ODU	US Probe Glen Allen, VA	\$406,000	\$536,000	\$450,000	5.5
Subtotal Round 3		\$1,261,000	\$3,672,000	\$9,600,000	5

Grand Round 4 - August 2015

GMU, VT	Ceres Nanosciences Manassas, VA	\$500,000	\$500,000	\$5,000,000	13
VT, UVA	First String Research Roanoke, VA and Mt. Pleasant, SC	\$290,000	\$500,000	\$3,500,000	2
ODU, EVMS	Embody LLC Norfolk, VA	\$634,500	\$725,000	\$3,600,000	5

Collaborators		Amount of Grant Award	Matching Funds	Follow on Funding	Job Creation (FTE)
VT, VCU	BioTherapeutics Inc. Blacksburg, VA	\$400,000	\$400,000	\$2,500,000	14
UVA, VCU	BrightSpec, Inc Charlottesville, VA	\$400,000	\$400,000	\$2,150,000	6
Subtotal Round 4		\$2,224,500	\$2,525,000	\$16,750,000	27

Grand Round 5 - December 2015

UVA, GMU	Cavion Charlottesville, VA	\$306,985	\$352,862	\$26,100,000	2.5
VT, UVA	VoltMed, Inc. Blacksburg, VA	\$380,000	\$1,200,000	\$2,000,000	12
Subtotal Round 5		\$686,985	\$1,552,862	\$28,100,000	14.5

Grand Round 6 - October 2016

VT, UVA	VoltMed, Inc. Blacksburg, VA	\$800,000	\$800,000	\$3,894,000	8
VT, VCU	BioTherapeutics Inc. Blacksburg, VA	\$800,000	\$800,000	\$70,600,000	12
GMU, VCU	Serpin Pharma Manassas, VA	\$400,000	\$3,400,000	\$2,700,000	4.5
EVMS, GMU	Sanyal Biotechnology Virginia Beach, VA	\$100,000	\$100,000	\$580,000	3
ODU, EVMS	Pulse Biosciences Burlingame, CA	\$300,000	\$300,000	\$5,361,863	2
VCU, UVA	Propagenix Rockville, MD	\$425,000	\$1,200,000	\$220,000	1
Subtotal Round 6		\$2,825,000	\$6,600,000	\$83,355,863	29.5

Grand Round 7 - July 2017

VCU, VT, Inova	Indivior, Inc. Richmond, VA	\$500,000	\$500,000	\$0	2
UVA, VT, Carilion	BRAINBox, LLC Richmond, VA	\$500,000	\$500,000	\$0	2
EVMS, VCU	ReAlta Life Sciences, LLC Norfolk, VA	\$400,000	\$400,000	\$12,000,000	4
Subtotal Round 7		\$1,400,000	\$1,400,000	\$12,000,000	8

Grand Round 8 - June 2018

VCU-UVA-VT	BrightSpec, Inc. Charlottesville, VA	\$400,000	\$400,000	\$1,850,000	2
VT, UVA	Continuum Biosciences, Inc. Blacksburg, VA	\$400,000	\$800,000	\$4,289,000	9
ODU, UVA	Embody, LLC Norfolk, VA	\$800,000	\$2,400,000	\$950,000	5
ODU, EVMS	LifeNet Health Virginia Beach, VA	\$250,000	\$250,000	\$0	3

Collaborators		Amount of Grant Award	Matching Funds	Follow on Funding	Job Creation (FTE)
GMU, VCU	Serpin Pharma Manassas, VA	\$350,000	\$350,000	\$2,600,000	2
VCU, UVA	WynnVision, LLC Richmond, VA	\$510,000	\$1,491,266	\$2,616,107	5
Subtotal Round 8		\$2,710,000	\$5,691,266	\$12,305,107	26

Grand Round 9 - April 2019

VT, UVA	AgroSpheres, Inc. Charlottesville, VA	\$600,000	\$600,000	\$8,800,000	9
VCU, UVA, VT	BrightSpec, Inc. Charlottesville, VA	\$400,000	\$400,000	\$0	0
UVA, GMU	Ceres Nanoscience, Inc. Manassas, VA	\$600,000	\$1,200,000	\$0	5
UVA, EVMS	Perthera, Inc. McLean, VA	\$500,000	\$1,000,000	\$0	2
Subtotal Round 9		\$2,100,000	\$3,200,000	\$8,800,000	16

Grand Round 10 - October 2019

Open	VT, UVA	CytoRecovery, Inc. Blacksburg, VA	\$400,000	\$400,000	\$1,426,000	7
Open	VCU, UVA	InterLeukin Combinatorial Therapies, Inc. Richmond, VA	\$700,000	\$700,000	\$1,500,000	6
Open	UVA, VT	Lytos Technologies, LLC Charlottesville, VA	\$500,000	\$500,000	\$78,000	3.5
Open	GMU, UVA	Monet Pharmaceuticals Nokesville, VA	\$400,000	\$400,000	\$0	0
Open	UVA, VCU	RIVANNA Charlottesville, VA	\$800,000	\$800,000	\$4,289,837	4
	EVMS, VCU	Tympanogen Richmond, VA	\$500,000	\$1,500,000	\$1,325,000	3
Subtotal Round 10			\$3,300,000	\$4,300,000	\$8,618,837	23.5

Grand Round 11 - October 2020

open	UVA, VCU	Contraline Charlottesville, VA	\$600,000	\$1,005,000	\$0	0
open	GMU, EVMS, UVA	ISOThrive Healdsburg, CA	\$800,000	\$3,200,000	\$0	0
open	VCU, ODU	Meru Richmond, VA	\$700,000	\$700,000	\$1,089,000	7
Subtotal Round 11			\$2,100,000	\$4,905,000	\$1,089,000	7

As of September 30, 2021: \$21,261,214 \$39,339,128 \$245,673,807 206

[remainder of this page intentionally left blank]

D.3 Summary of COVID-19 Grant Round

D.3.a. Members of Subject Matter Expert Consultant Panel

The following individuals were selected by the Virginia Catalyst Board of Directors to serve as subject matter experts (SME) for purposes of conducting the COVID-19 Grant Round:

- **Antonio Abbte, MD, PhD**
 'Roberts' Professor of Cardiology,
 Medical Director Clinical Research Unit
 Associate Director of the 'Write' Center for Clinical and Translational Research
 Virginia Commonwealth University, Richmond, VA
- **Carla Finkelstein, PhD**
 Scientific Director, Molecular Diagnostics Laboratory
 Fralin Biomedical Research Institute, Roanoke, VA
- **Arun Sanyal, MD**
 Professor of Medicine, Associate Director Education Core Center for Clinical and
 Translational Research
 Virginia Commonwealth University, Richmond, VA
- **Paul Skolnik, MD, FACP, FIDSA**
 Chair and Professor of Medicine, Virginia Tech Carilion
 Senior Vice President, Carilion Clinic, Roanoke, VA

D.3.b. Summary of Awarded Projects

University of Virginia

PBM C19 Research, LLC
 Charlottesville, VA

Company status: active

Clinical Trial of Dupilumab to Block IL-13 in Severe COVID-19

Old Dominion University

ReAlta Life Sciences
 Norfolk, VA
<https://realtalifesciences.com/>

Company status: active

RLS-0071 to Treat Acute Lung Injury Related to COVID-19

University of Virginia

Serpin Pharma, LLC
 Manassas, VA
<https://serpinpharma.com/>

Company status: active

SP16 as a Therapeutic for SARS-CoV-2 Induced ARDS

D.3.c. Summary of Economic Returns to Date

Collaborators	Amount of Grant Award	Matching Funds	Follow on Funding	Job Creation (FTE)
---------------	-----------------------	----------------	-------------------	--------------------

COVID-19 Grant Round - March 2021

open	UVA	PBM C19 Research, LLC Charlottesville, VA	\$345,000	\$345,000	\$0	2
open	ODU	ReAlta Life Sciences Norfolk, VA	\$3,390,000	\$3,390,000	\$0	0
open	UVA	Serpin Pharma Manassas, VA	\$1,250,000	\$2,350,000	\$1,271,778	7
	Total COVID-19 Round		\$4,985,000	\$6,085,000	\$1,271,778	9

[remainder of this page intentionally left blank]

Appendix E: Press Releases

E.1 Grant Round 11: Awarded Projects



FOR IMMEDIATE RELEASE

Media Contact:

A.J. Guenther

Yes&

(703) 823-1600

aj@yesandagency.com

Virginia Catalyst Awards \$2.1 Million in Grants to Virginia Companies and Universities to Foster Innovation in the Life Sciences

Three collaborative projects to address major unmet healthcare needs, drive economic growth in Virginia

RICHMOND, VA – October 26, 2020 – The Virginia Catalyst, formerly known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded \$2.1 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded as Round 11 of Virginia Catalyst’s ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth.

“The life sciences industry has been a catalyst for economic growth during the pandemic and is poised to accelerate Virginia’s recovery in a post COVID world,” said Mike Grisham, CEO, Virginia Catalyst. “Through programs like these grant initiatives, Virginia Catalyst and the Commonwealth of Virginia are investing in the future by driving additional capital and business opportunity through the life sciences. The funding we provide for these innovative programs helps generate significant outside capital and interest in Virginia. We are proud to announce the awardees for our eleventh round of funding as we help to finance the commercialization of Virginia’s innovations and investment in research infrastructure tools to facilitate bioscience research.”

Including this eleventh round of funding, Virginia Catalyst has awarded 46 grants totaling \$21.2 million, resulting in over \$37.5 million in matching funds and an additional \$194 million in follow-on funding to date.

The awards, which range from \$200,000 to \$800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:

- Funding innovative, collaborative, translational research projects that elevate the level of sponsored research at Virginia's universities and have the potential to significantly improve human health and create high value jobs in the Commonwealth
- Accelerating commercialization of Virginia research university inventions and discoveries and to achieve competitive critical mass through robust collaborations of Virginia research universities and industry

Round 11 of grant funding project winners:

Project: Clinical Translation of a Male Contraceptive Procedure

- Company: Contraline, Inc. (Charlottesville, VA)
- University collaborators: University of Virginia and Virginia Commonwealth University
- Funding amount: \$600,000

Project: Treating chronic Disease Caused by Microbiome Dysbiosis

- Company: ISOThrive, Inc. (Manassas, VA)
- University collaborators: George Mason University, Eastern Virginia Medical School, and University of Virginia
- Funding amount: \$800,000

Project: Innovative Bioanalytical Instrument for Improving Drug Discovery

- Company: Meru Biotechnologies (Richmond, VA)
- University collaborators: Virginia Commonwealth University and Old Dominion University
- Funding amount: \$700,000

Supporting Quotes

"Meru Bio is delighted to be selected by Virginia Catalyst for a Round 11 award. Our goal is to advance human health by optimizing the molecular binding analysis method of Free Solution Analysis (FSA) for the design and development of new drug therapies and diagnostics. For this award, our research team led by Dr. Ralph Martel will work collaboratively with Dr. Abdelwahed of VCU and Dr. Qian of ODU to develop a Label-Free Bioanalytical Instrument for Improving Drug Discovery. This award will help accelerate our path to market and significantly improve our ability to attract additional investments. We are looking forward to growing our company, right here in Richmond, VA."

- Dan Rodenhaver, Co-Founder and Chief Executive Officer of Meru Biotechnologies, Inc.

"Nearly half of all pregnancies in the United States each year are unintended, with three-fourths of couples relying on the female partner for birth control. Currently, men's options are

limited to condoms and vasectomy, creating a substantial opportunity for a novel male contraceptive to contribute to family planning and improved quality of life. Contraline, a spin-out from UVA, is a medical device company developing ADAM™, the world's first injectable hydrogel designed to provide long-lasting barrier contraception for men. The hydrogel is inserted into the vas deferens through a quick outpatient procedure, which has been shown to be safe and effective in large animal studies. The Virginia Catalyst grant will support our translational research collaborating with UVA and VCU urology departments to ready our male contraceptive ADAM™ for a first-in-human clinical trial in 2021. This will be the first clinical trial conducted on a non-hormonal male contraceptive device in over 20 years and we are excited to partner with Virginia Catalyst to enable it.”

- Kevin Eisenfrats, Co-Founder and Chief Executive Officer, Contraline, Inc.

“Treatment of Gastroesophageal Reflux Disease (GERD), one of the most ubiquitous global diseases, needs a new approach. The current standard of care is daily use of acid reducing medications known as proton pump inhibitors (PPIs). Yet, 40% of patients remain symptomatic. Nearly half of GERD patients are seeking an alternative treatment due to documented health concerns related to long-term use. ISOThrive’s game-changing treatment is targeted at resolving inflammation in the esophagus caused by bacterial dysbiosis, thereby resolving GERD at the root cause. Our novel treatment may also reduce the risk of Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC). This grant will allow ISOThrive to achieve our next major product development milestone and business inflection point by funding our Phase 2A clinical study to treat GERD with our patented non-digestible carbohydrate ISOT-101. Immediately after the successful completion of this study, ISOThrive intends to begin planning and construction of a new cGMP manufacturing facility in Virginia. This peer-reviewed Virginia Catalyst award is a vote of confidence in ISOThrive’s experienced team and the deep collaboration we have established with three of Virginia’s world class researchers and universities, Emanuel Petricoin, PhD (George Mason University), David Johnson, MD (Eastern Virginia Medical School), and Jeanetta Frye, MD (University of Virginia).”

- Jack Oswald, Co-Founder, CEO and CTO of ISOThrive Inc.

About Virginia Catalyst

Virginia Biosciences Health Research Corporation (VBHRC), known as Virginia Catalyst, has a vision of advancing life sciences throughout Virginia as a means of addressing large unmet medical needs to improve human health and to create high-paying jobs throughout the Commonwealth. Funded by the Virginia General Assembly’s General fund, the University of Virginia, Virginia Commonwealth University, Virginia Tech, Eastern Virginia Medical School, George Mason University, Old Dominion University, and William and Mary, Virginia Catalyst has funding opportunities to support collaborative projects in the Commonwealth. For more information, visit www.virginiacatalyst.org.

###

E.2 COVID-19 Grant Round: Call for Proposals



FOR IMMEDIATE RELEASE

Media Contact:

A.J. Guenther

Yes&

(703) 338-5657

aj@yesandagency.com

Virginia Catalyst Announces COVID-19 Grant Funding

Therapeutics for life-threatening symptoms associated with COVID-19

Now accepting applications for this special COVID-19 Grant Round

RICHMOND, VA – January 28, 2021 – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is conducting a formalized, competitive, one-time COVID-19 Therapeutic Drug Grant Funding Round of up to \$5,000,000 to:

- Support the acceleration of clinical testing by one or more Virginia companies of a therapeutic drug that treats life-threatening symptoms caused by COVID-19
- Encourage collaborative partnerships between investigators at one or more Virginia research universities and each grant recipient
- Increase Virginia's national and global competitiveness in the life sciences by creating critical mass through collaborations between and among Virginia's research universities and industry partners
- Create investment or jobs in Virginia

The Catalyst is now accepting applications for this special COVID-19 Grant Round.

Applications must be received by February 19, 2021 at 5:00 PM EST. Applications will be reviewed by a panel of independent hired consultants affiliated with Virginia research universities, and scored by an independent review team of scientists, venture capitalists and CEOs of Virginia-based life science companies. Qualified application teams will be invited to present their proposal (virtually) on March 18, 2021. Awards will be announced March 26, 2021. The application form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.viriniacatalyst.org/apply.html).

"We are excited to be able to provide this funding in order to advance therapeutics that address life-threatening symptoms associated with COVID," said Mike Grisham, CEO, Virginia Catalyst.

"Through our Grant Round program, the Virginia Catalyst continues to support teams of investigators from research institutions and industry to move their discoveries in the life sciences from laboratories to commercialization. Cumulatively through the first eleven funding rounds, Virginia Catalyst has dedicated a total of \$21.2 million for 46 collaborative projects. Together, these projects have created over 200 new jobs and have attracted an additional \$231.5 million of investment capital from venture

capital, private equity, corporations and government agencies including DARPA, NIH and NSF. With this special round of funding, the Virginia Catalyst will serve to support the advancement of these greatly needed life-saving therapeutics and help further strengthen Virginia's life sciences."

About Virginia Catalyst

Virginia Biosciences Health Research Corporation (VBHRC), known as Virginia Catalyst, has a vision of advancing life sciences throughout Virginia as a means of addressing large unmet medical needs to improve human health and to create high-paying jobs throughout the Commonwealth. Funded by the Virginia General Assembly's General fund, the University of Virginia, Virginia Commonwealth University, Virginia Tech, Eastern Virginia Medical School, George Mason University, Old Dominion University, and William and Mary, the Virginia Catalyst has funding opportunities to support collaborative life science projects in the Commonwealth. For more information, visit www.viriniacatalyst.org.

###

[remainder of this page intentionally left blank]

E.3 Grant Round 12: Call for Proposals



FOR IMMEDIATE RELEASE

Media Contact:

A.J. Guenther

Yes&

(703) 338-5657

aj@yesandagency.com

Virginia Catalyst Announces Round 12 of Grant Funding

Continuing to support collaborations between Virginia research universities and industry

RICHMOND, VA – March 30, 2021– The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 12 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

Virginia Catalyst awards these funds to help accelerate translational research and the commercialization of Virginia’s innovations. The awards, which range from \$200,000 to \$800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:

- Funding innovative, collaborative, translational research projects that elevate the level of sponsored research at Virginia’s universities and have the potential to create high value jobs in the Commonwealth
- Accelerating commercialization of Virginia research university inventions and discoveries and to achieve competitive critical mass through robust collaborations across Virginia

Letters of Intent (LOI) must be received by June 15, 2021 at 5:00 PM EDT. Projects that meet criteria will be invited to submit a full application by July 22, 2021. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to virtually present their proposal on Wednesday, September 8, 2021. Awards will be announced at the end of September 2021. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH and philanthropic foundations. This webinar can be viewed, and the slides downloaded on the home page of Virginia Catalyst at: <https://www.virginiacatalyst.org/>

“We believe in the power of collaborations and are committed to supporting teams of investigators from research institutions and industry to move their life science discoveries from laboratories to commercialization,” said Mike Grisham, CEO, Virginia Catalyst. “Funding through the Virginia Catalyst Grant Rounds fosters collaborative teams to work together to innovate and commercialize

innovations from our research universities and our life science companies. This results in greater capital formation, job creation and sustainable growth. Cumulatively through the first eleven funding rounds, Virginia Catalyst has dedicated a total of \$21.2 million for 46 collaborative projects. Together, these projects have created over 200 new jobs and have attracted an additional \$231 million of investment capital from venture capital, private equity, corporations and government agencies including DARPA, NIH and NSF. We are proud to continue supporting research investigators and entrepreneurs in achieving value for Virginia and the nation.

About Virginia Catalyst

Virginia Biosciences Health Research Corporation (VBHRC), known as Virginia Catalyst, has a vision of advancing life sciences throughout Virginia as a means of addressing large unmet medical needs to improve human health and to create high-paying jobs throughout the Commonwealth. Funded by the Virginia General Assembly's General fund, the University of Virginia, Virginia Commonwealth University, Virginia Tech, Eastern Virginia Medical School, George Mason University, Old Dominion University, and William and Mary, the Virginia Catalyst has funding opportunities to support collaborative life science projects in the Commonwealth. For more information, visit www.viriniacatalyst.org.

###

End of VBHRC Virginia Catalyst: Annual Report FY21